US20190050525A1 - Rieske-type oxygenase/reductase targeted drugs for diagnostic and treatment of diseases - Google Patents
Rieske-type oxygenase/reductase targeted drugs for diagnostic and treatment of diseases Download PDFInfo
- Publication number
- US20190050525A1 US20190050525A1 US16/103,830 US201816103830A US2019050525A1 US 20190050525 A1 US20190050525 A1 US 20190050525A1 US 201816103830 A US201816103830 A US 201816103830A US 2019050525 A1 US2019050525 A1 US 2019050525A1
- Authority
- US
- United States
- Prior art keywords
- methyl
- condition
- acid
- phylum
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 101710185971 3-ketosteroid-9-alpha-monooxygenase, ferredoxin reductase component Proteins 0.000 title claims description 5
- 101710154260 3-ketosteroid-9-alpha-monooxygenase, oxygenase component Proteins 0.000 title claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 5
- 239000003814 drug Substances 0.000 title description 4
- 229940079593 drug Drugs 0.000 title description 4
- 201000010099 disease Diseases 0.000 title description 3
- 108090000854 Oxidoreductases Proteins 0.000 title description 2
- 102000004316 Oxidoreductases Human genes 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 275
- 108090000790 Enzymes Proteins 0.000 claims abstract description 229
- 102000004190 Enzymes Human genes 0.000 claims abstract description 229
- 244000005700 microbiome Species 0.000 claims abstract description 112
- 238000000034 method Methods 0.000 claims abstract description 80
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 62
- UYPYRKYUKCHHIB-UHFFFAOYSA-N trimethylamine N-oxide Chemical compound C[N+](C)(C)[O-] UYPYRKYUKCHHIB-UHFFFAOYSA-N 0.000 claims abstract description 59
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims description 163
- 241000192125 Firmicutes Species 0.000 claims description 94
- 241000192142 Proteobacteria Species 0.000 claims description 93
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical class C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 39
- 150000003839 salts Chemical class 0.000 claims description 34
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- 238000003032 molecular docking Methods 0.000 claims description 15
- 238000004088 simulation Methods 0.000 claims description 15
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 claims description 14
- LHXDLQBQYFFVNW-XCBNKYQSSA-N (+)-fenchone Chemical compound C1C[C@]2(C)C(=O)C(C)(C)[C@H]1C2 LHXDLQBQYFFVNW-XCBNKYQSSA-N 0.000 claims description 13
- VAJVDSVGBWFCLW-UHFFFAOYSA-N 3-Phenyl-1-propanol Chemical compound OCCCC1=CC=CC=C1 VAJVDSVGBWFCLW-UHFFFAOYSA-N 0.000 claims description 13
- LUJMEECXHPYQOF-UHFFFAOYSA-N 3-hydroxyacetophenone Chemical compound CC(=O)C1=CC=CC(O)=C1 LUJMEECXHPYQOF-UHFFFAOYSA-N 0.000 claims description 13
- IJFXRHURBJZNAO-UHFFFAOYSA-N 3-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC(O)=C1 IJFXRHURBJZNAO-UHFFFAOYSA-N 0.000 claims description 13
- FNYDIAAMUCQQDE-UHFFFAOYSA-N 4-methylbenzene-1,3-diol Chemical compound CC1=CC=C(O)C=C1O FNYDIAAMUCQQDE-UHFFFAOYSA-N 0.000 claims description 13
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 claims description 13
- XRAMJHXWXCMGJM-UHFFFAOYSA-N methyl 3-(4-hydroxyphenyl)propionate Chemical compound COC(=O)CCC1=CC=C(O)C=C1 XRAMJHXWXCMGJM-UHFFFAOYSA-N 0.000 claims description 13
- ODLMAHJVESYWTB-UHFFFAOYSA-N propylbenzene Chemical compound CCCC1=CC=CC=C1 ODLMAHJVESYWTB-UHFFFAOYSA-N 0.000 claims description 13
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 12
- DUXCSEISVMREAX-UHFFFAOYSA-N 3,3-dimethylbutan-1-ol Chemical compound CC(C)(C)CCO DUXCSEISVMREAX-UHFFFAOYSA-N 0.000 claims description 10
- XSONSBDQIFBIOY-UHFFFAOYSA-N 2-phenoxyacetohydrazide Chemical compound NNC(=O)COC1=CC=CC=C1 XSONSBDQIFBIOY-UHFFFAOYSA-N 0.000 claims description 8
- DPDSFQSSCBFWBA-UHFFFAOYSA-N 2h-isoindole-1,3-diamine Chemical compound C1=CC=CC2=C(N)NC(N)=C21 DPDSFQSSCBFWBA-UHFFFAOYSA-N 0.000 claims description 8
- XAIUACHCJPWUEF-UHFFFAOYSA-N 3-azabicyclo[3.3.1]nonane Chemical compound C1NCC2CCCC1C2 XAIUACHCJPWUEF-UHFFFAOYSA-N 0.000 claims description 8
- PZNLKKRMQOCPGG-UHFFFAOYSA-N 3-phenyl-1h-pyrazole-5-carbohydrazide Chemical compound N1C(C(=O)NN)=CC(C=2C=CC=CC=2)=N1 PZNLKKRMQOCPGG-UHFFFAOYSA-N 0.000 claims description 8
- MASUVUIWOXJJKH-UHFFFAOYSA-N 4-methyl-3-phenyl-1,2-oxazol-5-amine Chemical compound CC1=C(N)ON=C1C1=CC=CC=C1 MASUVUIWOXJJKH-UHFFFAOYSA-N 0.000 claims description 8
- 201000001320 Atherosclerosis Diseases 0.000 claims description 8
- 206010068233 Trimethylaminuria Diseases 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- 230000002503 metabolic effect Effects 0.000 claims description 8
- CXGFWBPQQXZELI-UHFFFAOYSA-N n-ethylpyridin-2-amine Chemical compound CCNC1=CC=CC=N1 CXGFWBPQQXZELI-UHFFFAOYSA-N 0.000 claims description 8
- DBGFNLVRAFYZBI-UHFFFAOYSA-N n-methylpyridin-3-amine Chemical compound CNC1=CC=CN=C1 DBGFNLVRAFYZBI-UHFFFAOYSA-N 0.000 claims description 8
- CRPUJAZIXJMDBK-BDAKNGLRSA-N (-)-camphene Chemical compound C1C[C@H]2C(=C)C(C)(C)[C@@H]1C2 CRPUJAZIXJMDBK-BDAKNGLRSA-N 0.000 claims description 7
- GYUSHSKDGRZQOB-SSDOTTSWSA-N (1r)-2-methylcyclohexa-2,5-diene-1-carboxylic acid Chemical compound CC1=CCC=C[C@H]1C(O)=O GYUSHSKDGRZQOB-SSDOTTSWSA-N 0.000 claims description 7
- VZRRCQOUNSHSGB-XSSZXYGBSA-N (1r,4s,5r)-4-hydroxy-4,6,6-trimethylbicyclo[3.1.1]heptan-3-one Chemical compound C1[C@@H]2C(C)(C)[C@H]1CC(=O)[C@]2(O)C VZRRCQOUNSHSGB-XSSZXYGBSA-N 0.000 claims description 7
- YVHAOWGRHCPODY-YFKPBYRVSA-N (2r)-3,3-dimethylbutane-1,2-diol Chemical compound CC(C)(C)[C@@H](O)CO YVHAOWGRHCPODY-YFKPBYRVSA-N 0.000 claims description 7
- WVYWICLMDOOCFB-ZCFIWIBFSA-N (2r)-4-methylpentan-2-ol Chemical compound CC(C)C[C@@H](C)O WVYWICLMDOOCFB-ZCFIWIBFSA-N 0.000 claims description 7
- FCOUHTHQYOMLJT-MRVPVSSYSA-N (2r)-6-methylheptan-2-ol Chemical compound CC(C)CCC[C@@H](C)O FCOUHTHQYOMLJT-MRVPVSSYSA-N 0.000 claims description 7
- KJBPYIUAQLPHJG-VIFPVBQESA-N (2s)-1-phenylmethoxypropan-2-ol Chemical compound C[C@H](O)COCC1=CC=CC=C1 KJBPYIUAQLPHJG-VIFPVBQESA-N 0.000 claims description 7
- WTLNOANVTIKPEE-VKHMYHEASA-N (2s)-2-acetyloxypropanoic acid Chemical compound OC(=O)[C@H](C)OC(C)=O WTLNOANVTIKPEE-VKHMYHEASA-N 0.000 claims description 7
- MWCBGWLCXSUTHK-YFKPBYRVSA-N (2s)-2-methylbutane-1,4-diol Chemical compound OC[C@@H](C)CCO MWCBGWLCXSUTHK-YFKPBYRVSA-N 0.000 claims description 7
- YVHAOWGRHCPODY-RXMQYKEDSA-N (2s)-3,3-dimethylbutane-1,2-diol Chemical compound CC(C)(C)[C@H](O)CO YVHAOWGRHCPODY-RXMQYKEDSA-N 0.000 claims description 7
- MXLMTQWGSQIYOW-YFKPBYRVSA-N (2s)-3-methylbutan-2-ol Chemical compound CC(C)[C@H](C)O MXLMTQWGSQIYOW-YFKPBYRVSA-N 0.000 claims description 7
- WVYWICLMDOOCFB-LURJTMIESA-N (2s)-4-methylpentan-2-ol Chemical compound CC(C)C[C@H](C)O WVYWICLMDOOCFB-LURJTMIESA-N 0.000 claims description 7
- JYVLIDXNZAXMDK-YFKPBYRVSA-N (2s)-pentan-2-ol Chemical compound CCC[C@H](C)O JYVLIDXNZAXMDK-YFKPBYRVSA-N 0.000 claims description 7
- QGMMKSUHQMVLRO-UHFFFAOYSA-N (3-amino-2-bicyclo[2.2.1]heptanyl)methanol Chemical compound C1CC2C(N)C(CO)C1C2 QGMMKSUHQMVLRO-UHFFFAOYSA-N 0.000 claims description 7
- JCTXKRPTIMZBJT-SSDOTTSWSA-N (3r)-2,2,4-trimethylpentane-1,3-diol Chemical compound CC(C)[C@@H](O)C(C)(C)CO JCTXKRPTIMZBJT-SSDOTTSWSA-N 0.000 claims description 7
- VLIQJGACTLGWCQ-UHFFFAOYSA-N (4-methylpyridin-3-yl)methanamine Chemical compound CC1=CC=NC=C1CN VLIQJGACTLGWCQ-UHFFFAOYSA-N 0.000 claims description 7
- YDSUJYPZJPWCOL-ZCFIWIBFSA-N (4r)-4-amino-1-propylpyrrolidin-2-one Chemical compound CCCN1C[C@H](N)CC1=O YDSUJYPZJPWCOL-ZCFIWIBFSA-N 0.000 claims description 7
- GIGQFINHHUTCAQ-UHFFFAOYSA-N (5-methylfuro[2,3-b]pyridin-2-yl)methanol Chemical compound CC1=CN=C2OC(CO)=CC2=C1 GIGQFINHHUTCAQ-UHFFFAOYSA-N 0.000 claims description 7
- RTHDLBGPIRDCFJ-CYBMUJFWSA-N (5r)-5-naphthalen-2-yloxolan-2-one Chemical compound O1C(=O)CC[C@@H]1C1=CC=C(C=CC=C2)C2=C1 RTHDLBGPIRDCFJ-CYBMUJFWSA-N 0.000 claims description 7
- VTWKXBJHBHYJBI-SOFGYWHQSA-N (ne)-n-benzylidenehydroxylamine Chemical compound O\N=C\C1=CC=CC=C1 VTWKXBJHBHYJBI-SOFGYWHQSA-N 0.000 claims description 7
- LHAJIBPLECWWQP-UHFFFAOYSA-N 1-cyclopent-2-en-1-ylpropan-2-one Chemical compound CC(=O)CC1CCC=C1 LHAJIBPLECWWQP-UHFFFAOYSA-N 0.000 claims description 7
- BPBNKCIVWFCMJY-UHFFFAOYSA-N 1-ethynyl-4-phenylbenzene Chemical group C1=CC(C#C)=CC=C1C1=CC=CC=C1 BPBNKCIVWFCMJY-UHFFFAOYSA-N 0.000 claims description 7
- PUEWSNLDTZQXLN-UHFFFAOYSA-N 1-pyridin-3-ylpropan-2-amine Chemical compound CC(N)CC1=CC=CN=C1 PUEWSNLDTZQXLN-UHFFFAOYSA-N 0.000 claims description 7
- WNJSKZBEWNVKGU-UHFFFAOYSA-N 2,2-dimethoxyethylbenzene Chemical compound COC(OC)CC1=CC=CC=C1 WNJSKZBEWNVKGU-UHFFFAOYSA-N 0.000 claims description 7
- YBVRFTBNIZWMSK-UHFFFAOYSA-N 2,2-dimethyl-1-phenylpropan-1-ol Chemical compound CC(C)(C)C(O)C1=CC=CC=C1 YBVRFTBNIZWMSK-UHFFFAOYSA-N 0.000 claims description 7
- UYXWKABXDGYZSR-UHFFFAOYSA-N 2-(2,3-dihydro-1h-inden-5-yl)-2-oxoacetic acid Chemical compound OC(=O)C(=O)C1=CC=C2CCCC2=C1 UYXWKABXDGYZSR-UHFFFAOYSA-N 0.000 claims description 7
- JUNAPQMUUHSYOV-UHFFFAOYSA-N 2-(2h-tetrazol-5-yl)acetic acid Chemical compound OC(=O)CC=1N=NNN=1 JUNAPQMUUHSYOV-UHFFFAOYSA-N 0.000 claims description 7
- QEQDLKUMPUDNPG-UHFFFAOYSA-N 2-(7-amino-4-methyl-2-oxochromen-3-yl)acetic acid Chemical compound C1=C(N)C=CC2=C1OC(=O)C(CC(O)=O)=C2C QEQDLKUMPUDNPG-UHFFFAOYSA-N 0.000 claims description 7
- UUDNITWWYBIYOX-RNFRBKRXSA-N 2-[(1R,4R)-2-azabicyclo[2.2.1]heptan-2-yl]acetic acid Chemical compound OC(=O)CN1C[C@@H]2CC[C@@H]1C2 UUDNITWWYBIYOX-RNFRBKRXSA-N 0.000 claims description 7
- NGFPWHGISWUQOI-MRVPVSSYSA-N 2-[(2r)-butan-2-yl]phenol Chemical compound CC[C@@H](C)C1=CC=CC=C1O NGFPWHGISWUQOI-MRVPVSSYSA-N 0.000 claims description 7
- QTSPVDJDIGIJGX-UHFFFAOYSA-N 2-[3-(4-methylphenyl)-1,2-oxazol-5-yl]ethanol Chemical compound C1=CC(C)=CC=C1C1=NOC(CCO)=C1 QTSPVDJDIGIJGX-UHFFFAOYSA-N 0.000 claims description 7
- TZYRSLHNPKPEFV-UHFFFAOYSA-N 2-ethyl-1-butanol Chemical compound CCC(CC)CO TZYRSLHNPKPEFV-UHFFFAOYSA-N 0.000 claims description 7
- OSSPZRHEHZZDSX-UHFFFAOYSA-N 2-methoxy-4-phenylbenzaldehyde Chemical compound C1=C(C=O)C(OC)=CC(C=2C=CC=CC=2)=C1 OSSPZRHEHZZDSX-UHFFFAOYSA-N 0.000 claims description 7
- IWTFOFMTUOBLHG-UHFFFAOYSA-N 2-methoxypyridine Chemical compound COC1=CC=CC=N1 IWTFOFMTUOBLHG-UHFFFAOYSA-N 0.000 claims description 7
- OBCSAIDCZQSFQH-UHFFFAOYSA-N 2-methyl-1,4-phenylenediamine Chemical compound CC1=CC(N)=CC=C1N OBCSAIDCZQSFQH-UHFFFAOYSA-N 0.000 claims description 7
- VDULOAUXSMYUMG-UHFFFAOYSA-N 2-phenyl-1h-quinazolin-4-one Chemical compound N=1C2=CC=CC=C2C(O)=NC=1C1=CC=CC=C1 VDULOAUXSMYUMG-UHFFFAOYSA-N 0.000 claims description 7
- DKXHSOUZPMHNIZ-UHFFFAOYSA-N 2-pyridin-4-yl-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one Chemical compound C=1C=2C(=O)NCCC=2NC=1C1=CC=NC=C1 DKXHSOUZPMHNIZ-UHFFFAOYSA-N 0.000 claims description 7
- FXHQNXLLFSHPJL-UHFFFAOYSA-N 3-(1,3-dioxoisoindol-2-yl)benzonitrile Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1=CC=CC(C#N)=C1 FXHQNXLLFSHPJL-UHFFFAOYSA-N 0.000 claims description 7
- ZOXCMZXXNOSBHU-UHFFFAOYSA-N 3-(4-methoxyphenyl)propanal Chemical compound COC1=CC=C(CCC=O)C=C1 ZOXCMZXXNOSBHU-UHFFFAOYSA-N 0.000 claims description 7
- OFKWWALNMPEOSZ-UHFFFAOYSA-N 3-(hydrazinylmethyl)phenol Chemical compound NNCC1=CC=CC(O)=C1 OFKWWALNMPEOSZ-UHFFFAOYSA-N 0.000 claims description 7
- ULOFGMFUHYQYFS-UHFFFAOYSA-N 3-[5-(3-methylphenyl)-1,3,4-oxadiazol-2-yl]propanoic acid Chemical compound CC1=CC=CC(C=2OC(CCC(O)=O)=NN=2)=C1 ULOFGMFUHYQYFS-UHFFFAOYSA-N 0.000 claims description 7
- FLROJJGKUKLCAE-UHFFFAOYSA-N 3-amino-2-methylphenol Chemical compound CC1=C(N)C=CC=C1O FLROJJGKUKLCAE-UHFFFAOYSA-N 0.000 claims description 7
- IFSSSYDVRQSDSG-UHFFFAOYSA-N 3-ethenylaniline Chemical compound NC1=CC=CC(C=C)=C1 IFSSSYDVRQSDSG-UHFFFAOYSA-N 0.000 claims description 7
- MFKRHJVUCZRDTF-UHFFFAOYSA-N 3-methoxy-3-methylbutan-1-ol Chemical compound COC(C)(C)CCO MFKRHJVUCZRDTF-UHFFFAOYSA-N 0.000 claims description 7
- XPFCZYUVICHKDS-UHFFFAOYSA-N 3-methylbutane-1,3-diol Chemical compound CC(C)(O)CCO XPFCZYUVICHKDS-UHFFFAOYSA-N 0.000 claims description 7
- MXDRPNGTQDRKQM-UHFFFAOYSA-N 3-methylpyridazine Chemical compound CC1=CC=CN=N1 MXDRPNGTQDRKQM-UHFFFAOYSA-N 0.000 claims description 7
- YLNMGMIEOWFPRX-UHFFFAOYSA-N 3-pyridin-2-ylaniline Chemical compound NC1=CC=CC(C=2N=CC=CC=2)=C1 YLNMGMIEOWFPRX-UHFFFAOYSA-N 0.000 claims description 7
- VPANVNSDJSUFEF-UHFFFAOYSA-N 4,5-dimethyl-1,2-oxazol-3-amine Chemical compound CC=1ON=C(N)C=1C VPANVNSDJSUFEF-UHFFFAOYSA-N 0.000 claims description 7
- BBCYWHMUTPKZKJ-UHFFFAOYSA-N 4-(5-methyl-1h-1,2,4-triazol-3-yl)aniline Chemical compound N1C(C)=NC(C=2C=CC(N)=CC=2)=N1 BBCYWHMUTPKZKJ-UHFFFAOYSA-N 0.000 claims description 7
- YICAMJWHIUMFDI-UHFFFAOYSA-N 4-acetamidotoluene Chemical compound CC(=O)NC1=CC=C(C)C=C1 YICAMJWHIUMFDI-UHFFFAOYSA-N 0.000 claims description 7
- YORPCQSBLZIBKP-UHFFFAOYSA-N 4-methylpiperidin-1-ium-4-carboxylate Chemical compound OC(=O)C1(C)CCNCC1 YORPCQSBLZIBKP-UHFFFAOYSA-N 0.000 claims description 7
- XCJLBNVENUPHEA-UHFFFAOYSA-N 4-phenyl-2h-phthalazin-1-one Chemical compound C12=CC=CC=C2C(=O)NN=C1C1=CC=CC=C1 XCJLBNVENUPHEA-UHFFFAOYSA-N 0.000 claims description 7
- NYSUFKYXLDNHQN-UHFFFAOYSA-N 4-pyrrolidin-1-ium-1-ylbutanoate Chemical compound OC(=O)CCCN1CCCC1 NYSUFKYXLDNHQN-UHFFFAOYSA-N 0.000 claims description 7
- LIXHYYAASODLNG-UHFFFAOYSA-N 5-(1,3-benzodioxol-5-yl)-2-methylfuran-3-carboxylic acid Chemical compound OC(=O)C1=C(C)OC(C=2C=C3OCOC3=CC=2)=C1 LIXHYYAASODLNG-UHFFFAOYSA-N 0.000 claims description 7
- OFNBXLBLUCECGY-UHFFFAOYSA-N 5-(4-methylphenyl)-1h-1,2,4-triazol-3-amine Chemical compound C1=CC(C)=CC=C1C1=NC(N)=NN1 OFNBXLBLUCECGY-UHFFFAOYSA-N 0.000 claims description 7
- GVPFRVKDBZWRCZ-UHFFFAOYSA-N 5-(4-methylphenyl)-1h-pyrazol-3-amine Chemical compound C1=CC(C)=CC=C1C1=CC(N)=NN1 GVPFRVKDBZWRCZ-UHFFFAOYSA-N 0.000 claims description 7
- YZDIEQFFXQUBRM-UHFFFAOYSA-N 5-(4-methylphenyl)furan-2-carboxylic acid Chemical compound C1=CC(C)=CC=C1C1=CC=C(C(O)=O)O1 YZDIEQFFXQUBRM-UHFFFAOYSA-N 0.000 claims description 7
- UPPKQVVRCXNMAP-UHFFFAOYSA-N 8-methyl-4h-thieno[3,2-c]chromene-2-carboxylic acid Chemical compound C12=CC(C)=CC=C2OCC2=C1SC(C(O)=O)=C2 UPPKQVVRCXNMAP-UHFFFAOYSA-N 0.000 claims description 7
- MMNWSHJJPDXKCH-UHFFFAOYSA-N 9,10-dioxoanthracene-2-sulfonic acid Chemical compound C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 MMNWSHJJPDXKCH-UHFFFAOYSA-N 0.000 claims description 7
- FMKVRRYQWWPOAL-UHFFFAOYSA-N 9-ethynylphenanthrene Chemical compound C1=CC=C2C(C#C)=CC3=CC=CC=C3C2=C1 FMKVRRYQWWPOAL-UHFFFAOYSA-N 0.000 claims description 7
- JYXGIOKAKDAARW-UHFFFAOYSA-N N-(2-hydroxyethyl)iminodiacetic acid Chemical compound OCCN(CC(O)=O)CC(O)=O JYXGIOKAKDAARW-UHFFFAOYSA-N 0.000 claims description 7
- SWGXDLRCJNEEGZ-UHFFFAOYSA-N N-cyclohexylformamide Chemical compound O=CNC1CCCCC1 SWGXDLRCJNEEGZ-UHFFFAOYSA-N 0.000 claims description 7
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 claims description 7
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 claims description 7
- LUMNWCHHXDUKFI-XLPZGREQSA-N [(1s,4s,5s)-5-bicyclo[2.2.1]hept-2-enyl]methanol Chemical compound C1[C@@H]2[C@@H](CO)C[C@H]1C=C2 LUMNWCHHXDUKFI-XLPZGREQSA-N 0.000 claims description 7
- GGNQRNBDZQJCCN-UHFFFAOYSA-N benzene-1,2,4-triol Chemical compound OC1=CC=C(O)C(O)=C1 GGNQRNBDZQJCCN-UHFFFAOYSA-N 0.000 claims description 7
- YXVFYQXJAXKLAK-UHFFFAOYSA-N biphenyl-4-ol Chemical compound C1=CC(O)=CC=C1C1=CC=CC=C1 YXVFYQXJAXKLAK-UHFFFAOYSA-N 0.000 claims description 7
- ZXYBIPTYOWWVQD-UHFFFAOYSA-N bis(benzotriazol-1-yl)methanone Chemical compound N1=NC2=CC=CC=C2N1C(=O)N1C2=CC=CC=C2N=N1 ZXYBIPTYOWWVQD-UHFFFAOYSA-N 0.000 claims description 7
- WKDNYTOXBCRNPV-UHFFFAOYSA-N bpda Chemical compound C1=C2C(=O)OC(=O)C2=CC(C=2C=C3C(=O)OC(C3=CC=2)=O)=C1 WKDNYTOXBCRNPV-UHFFFAOYSA-N 0.000 claims description 7
- UBRCBHVOYDSGKZ-UHFFFAOYSA-N chembl1422046 Chemical compound NC1=CC=C(O)C(C=2SC3=CC=CC=C3N=2)=C1 UBRCBHVOYDSGKZ-UHFFFAOYSA-N 0.000 claims description 7
- KYUUPPKLZSVGMG-UHFFFAOYSA-N cyclobutanecarbohydrazide Chemical compound NNC(=O)C1CCC1 KYUUPPKLZSVGMG-UHFFFAOYSA-N 0.000 claims description 7
- HECLRDQVFMWTQS-QCLAVDOMSA-N endo-dicyclopentadiene Chemical compound C1[C@@H]2[C@H]3CC=C[C@H]3[C@H]1C=C2 HECLRDQVFMWTQS-QCLAVDOMSA-N 0.000 claims description 7
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 claims description 7
- AUHZEENZYGFFBQ-UHFFFAOYSA-N mesitylene Substances CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 claims description 7
- ITATYELQCJRCCK-MRVPVSSYSA-N methyl (2r)-2-hydroxy-2-phenylacetate Chemical compound COC(=O)[C@H](O)C1=CC=CC=C1 ITATYELQCJRCCK-MRVPVSSYSA-N 0.000 claims description 7
- CPHYEAKEGDBOMK-ONEGZZNKSA-N methyl (e)-3-(2-amino-5-methylpyridin-3-yl)prop-2-enoate Chemical compound COC(=O)\C=C\C1=CC(C)=CN=C1N CPHYEAKEGDBOMK-ONEGZZNKSA-N 0.000 claims description 7
- KMROKLMQVGAOMJ-UHFFFAOYSA-N methyl 4-methylpiperidine-4-carboxylate Chemical compound COC(=O)C1(C)CCNCC1 KMROKLMQVGAOMJ-UHFFFAOYSA-N 0.000 claims description 7
- UAKAWWHOQNNATR-UHFFFAOYSA-N n'-hydroxy-2-methylbenzenecarboximidamide Chemical compound CC1=CC=CC=C1C(N)=NO UAKAWWHOQNNATR-UHFFFAOYSA-N 0.000 claims description 7
- RGUVUPQQFXCJFC-UHFFFAOYSA-N n-hydroxyoctanamide Chemical compound CCCCCCCC(=O)NO RGUVUPQQFXCJFC-UHFFFAOYSA-N 0.000 claims description 7
- 235000016709 nutrition Nutrition 0.000 claims description 7
- DLRJIFUOBPOJNS-UHFFFAOYSA-N phenetole Chemical compound CCOC1=CC=CC=C1 DLRJIFUOBPOJNS-UHFFFAOYSA-N 0.000 claims description 7
- CWHFDTWZHFRTAB-UHFFFAOYSA-N phenyl cyanate Chemical compound N#COC1=CC=CC=C1 CWHFDTWZHFRTAB-UHFFFAOYSA-N 0.000 claims description 7
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 claims description 7
- GDESWOTWNNGOMW-UHFFFAOYSA-N resorcinol monobenzoate Chemical compound OC1=CC=CC(OC(=O)C=2C=CC=CC=2)=C1 GDESWOTWNNGOMW-UHFFFAOYSA-N 0.000 claims description 7
- 229930006714 (-)-camphene Natural products 0.000 claims description 6
- 229930006729 (1R,4S)-fenchone Natural products 0.000 claims description 6
- 229930006731 (1S,4R)-fenchone Natural products 0.000 claims description 6
- DXNKJRKPVQVDJW-RITPCOANSA-N (1r,2s)-2-aminocyclohexane-1-carboxamide Chemical compound N[C@H]1CCCC[C@H]1C(N)=O DXNKJRKPVQVDJW-RITPCOANSA-N 0.000 claims description 6
- ULGHUDXDTMIEAM-VIFPVBQESA-N (1s)-1-(2,5-dimethylphenyl)ethanamine Chemical compound C[C@H](N)C1=CC(C)=CC=C1C ULGHUDXDTMIEAM-VIFPVBQESA-N 0.000 claims description 6
- MXLMTQWGSQIYOW-RXMQYKEDSA-N (2r)-3-methylbutan-2-ol Chemical compound CC(C)[C@@H](C)O MXLMTQWGSQIYOW-RXMQYKEDSA-N 0.000 claims description 6
- JUTDHSGANMHVIC-JTQLQIEISA-N (2s)-2-phenylpyrrolidine Chemical compound C1CCN[C@@H]1C1=CC=CC=C1 JUTDHSGANMHVIC-JTQLQIEISA-N 0.000 claims description 6
- HMYXKHZCEYROAL-UHFFFAOYSA-N (4-chloro-2,3,5,6-tetrafluorophenyl)methanol Chemical compound OCC1=C(F)C(F)=C(Cl)C(F)=C1F HMYXKHZCEYROAL-UHFFFAOYSA-N 0.000 claims description 6
- YBKOPFQCLSPTPV-YVMONPNESA-N (nz)-n-(pyridin-3-ylmethylidene)hydroxylamine Chemical compound O\N=C/C1=CC=CN=C1 YBKOPFQCLSPTPV-YVMONPNESA-N 0.000 claims description 6
- FAHUKNBUIVOJJR-UHFFFAOYSA-N 1-(4-fluorophenyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine Chemical compound C1=CC(F)=CC=C1C1C2=CC=CN2CCN1 FAHUKNBUIVOJJR-UHFFFAOYSA-N 0.000 claims description 6
- HECLRDQVFMWTQS-RGOKHQFPSA-N 1755-01-7 Chemical compound C1[C@H]2[C@@H]3CC=C[C@@H]3[C@@H]1C=C2 HECLRDQVFMWTQS-RGOKHQFPSA-N 0.000 claims description 6
- UBJBKRMNBMMMHZ-UHFFFAOYSA-N 1h-indol-7-ylmethanol Chemical compound OCC1=CC=CC2=C1NC=C2 UBJBKRMNBMMMHZ-UHFFFAOYSA-N 0.000 claims description 6
- 229940075142 2,5-diaminotoluene Drugs 0.000 claims description 6
- AMCOCUDBDKVWRZ-UHFFFAOYSA-N 2-(2-hydroxyethoxy)phenol Chemical compound OCCOC1=CC=CC=C1O AMCOCUDBDKVWRZ-UHFFFAOYSA-N 0.000 claims description 6
- GHKSKVKCKMGRDU-UHFFFAOYSA-N 2-(3-aminopropylamino)ethanol Chemical compound NCCCNCCO GHKSKVKCKMGRDU-UHFFFAOYSA-N 0.000 claims description 6
- ZGQVZLSNEBEHFN-UHFFFAOYSA-N 2-(4-methylphenyl)benzonitrile Chemical compound C1=CC(C)=CC=C1C1=CC=CC=C1C#N ZGQVZLSNEBEHFN-UHFFFAOYSA-N 0.000 claims description 6
- QOBASENDLSYOKH-UHFFFAOYSA-N 2-(pyridin-3-ylmethylamino)ethanol Chemical compound OCCNCC1=CC=CN=C1 QOBASENDLSYOKH-UHFFFAOYSA-N 0.000 claims description 6
- KAWUBNUJMFOOOE-UHFFFAOYSA-N 3-amino-3-(3,5-dibromo-4-hydroxyphenyl)propanoic acid Chemical compound OC(=O)CC(N)C1=CC(Br)=C(O)C(Br)=C1 KAWUBNUJMFOOOE-UHFFFAOYSA-N 0.000 claims description 6
- RGDQRXPEZUNWHX-UHFFFAOYSA-N 3-methylpyridin-2-amine Chemical compound CC1=CC=CN=C1N RGDQRXPEZUNWHX-UHFFFAOYSA-N 0.000 claims description 6
- LUQVCHRDAGWYMG-UHFFFAOYSA-N 4-phenylbenzamide Chemical compound C1=CC(C(=O)N)=CC=C1C1=CC=CC=C1 LUQVCHRDAGWYMG-UHFFFAOYSA-N 0.000 claims description 6
- JXUWZXFVCBODAN-UHFFFAOYSA-N 5-methylpyridin-3-amine Chemical compound CC1=CN=CC(N)=C1 JXUWZXFVCBODAN-UHFFFAOYSA-N 0.000 claims description 6
- XLBVNMSMFQMKEY-BYPYZUCNSA-N N-methyl-L-glutamic acid Chemical compound CN[C@H](C(O)=O)CCC(O)=O XLBVNMSMFQMKEY-BYPYZUCNSA-N 0.000 claims description 6
- CRPUJAZIXJMDBK-UHFFFAOYSA-N Toxaphene Natural products C1CC2C(=C)C(C)(C)C1C2 CRPUJAZIXJMDBK-UHFFFAOYSA-N 0.000 claims description 6
- JHNURUNMNRSGRO-SSDOTTSWSA-N [(3r)-2,3-dihydro-1,4-benzodioxin-3-yl]methanamine Chemical compound C1=CC=C2O[C@H](CN)COC2=C1 JHNURUNMNRSGRO-SSDOTTSWSA-N 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- CLJMMQGDJNYDER-UHFFFAOYSA-N heptan-4-amine Chemical compound CCCC(N)CCC CLJMMQGDJNYDER-UHFFFAOYSA-N 0.000 claims description 6
- CTHCTLCNUREAJV-UHFFFAOYSA-N heptane-2,4,6-trione Chemical compound CC(=O)CC(=O)CC(C)=O CTHCTLCNUREAJV-UHFFFAOYSA-N 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- 125000001827 mesitylenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1C([H])([H])[H])C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- 230000035764 nutrition Effects 0.000 claims description 6
- AXCXHFKZHDEKTP-UHFFFAOYSA-N para-methoxycinnamaldehyde Natural products COC1=CC=C(C=CC=O)C=C1 AXCXHFKZHDEKTP-UHFFFAOYSA-N 0.000 claims description 6
- 229940067157 phenylhydrazine Drugs 0.000 claims description 6
- TXQWFIVRZNOPCK-UHFFFAOYSA-N pyridin-4-ylmethanamine Chemical compound NCC1=CC=NC=C1 TXQWFIVRZNOPCK-UHFFFAOYSA-N 0.000 claims description 6
- 229960000581 salicylamide Drugs 0.000 claims description 6
- DDUFYKNOXPZZIW-CRCLSJGQSA-N vince lactam Chemical compound C1[C@H]2C(=O)N[C@@H]1C=C2 DDUFYKNOXPZZIW-CRCLSJGQSA-N 0.000 claims description 6
- XPZYBFOYRKOKPL-MEKDEQNOSA-N (1s,5r)-3-azabicyclo[3.2.1]octan-8-ol Chemical compound C1NC[C@H]2CC[C@@H]1C2O XPZYBFOYRKOKPL-MEKDEQNOSA-N 0.000 claims description 5
- 208000007536 Thrombosis Diseases 0.000 claims description 5
- HYOWVAAEQCNGLE-JTQLQIEISA-N alpha-methyl-L-phenylalanine Chemical compound OC(=O)[C@](N)(C)CC1=CC=CC=C1 HYOWVAAEQCNGLE-JTQLQIEISA-N 0.000 claims description 5
- 108030004331 Choline trimethylamine-lyases Proteins 0.000 claims description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 4
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 35
- 229960001231 choline Drugs 0.000 description 35
- 230000003993 interaction Effects 0.000 description 25
- 238000002474 experimental method Methods 0.000 description 17
- 238000004519 manufacturing process Methods 0.000 description 15
- 230000006870 function Effects 0.000 description 11
- 238000013459 approach Methods 0.000 description 10
- 125000004429 atom Chemical group 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 108010057167 dimethylaniline monooxygenase (N-oxide forming) Proteins 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- WTARULDDTDQWMU-IUCAKERBSA-N (-)-β-pinene Chemical compound C1[C@@H]2C(C)(C)[C@H]1CCC2=C WTARULDDTDQWMU-IUCAKERBSA-N 0.000 description 7
- 238000004422 calculation algorithm Methods 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 6
- 230000006399 behavior Effects 0.000 description 6
- 238000005094 computer simulation Methods 0.000 description 6
- 230000002123 temporal effect Effects 0.000 description 6
- 238000004891 communication Methods 0.000 description 5
- 230000002596 correlated effect Effects 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 238000013528 artificial neural network Methods 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 244000005709 gut microbiome Species 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 150000007523 nucleic acids Chemical group 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 229930006715 (-)-beta-pinene Natural products 0.000 description 3
- 0 CCC1C(C)(C(C)*2)C2CC1 Chemical compound CCC1C(C)(C(C)*2)C2CC1 0.000 description 3
- 102100035041 Dimethylaniline monooxygenase [N-oxide-forming] 3 Human genes 0.000 description 3
- 108090000856 Lyases Proteins 0.000 description 3
- 102000004317 Lyases Human genes 0.000 description 3
- WTARULDDTDQWMU-UHFFFAOYSA-N Pseudopinene Natural products C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000013473 artificial intelligence Methods 0.000 description 3
- -1 at least one (e.g. Chemical class 0.000 description 3
- 229940050390 benzoate Drugs 0.000 description 3
- 229960004203 carnitine Drugs 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000006957 competitive inhibition Effects 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000007637 random forest analysis Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000015943 Coeliac disease Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000736262 Microbiota Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- YBKOPFQCLSPTPV-VMPITWQZSA-N O/N=C/C1=CN=CC=C1 Chemical compound O/N=C/C1=CN=CC=C1 YBKOPFQCLSPTPV-VMPITWQZSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 206010039792 Seborrhoea Diseases 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000005341 cation exchange Methods 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000002447 crystallographic data Methods 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 238000003066 decision tree Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 238000009499 grossing Methods 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 238000003064 k means clustering Methods 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000037312 oily skin Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000013488 ordinary least square regression Methods 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000092 prognostic biomarker Substances 0.000 description 2
- 238000013139 quantization Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- IHLRGGLJGGTPCY-HWKANZROSA-N (e)-hept-5-en-3-one Chemical compound CCC(=O)C\C=C\C IHLRGGLJGGTPCY-HWKANZROSA-N 0.000 description 1
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 1
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 1
- GTKIGDZXPDCIKR-UHFFFAOYSA-N 2-phenylbenzamide Chemical compound NC(=O)C1=CC=CC=C1C1=CC=CC=C1 GTKIGDZXPDCIKR-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- 208000036640 Asperger disease Diseases 0.000 description 1
- 201000006062 Asperger syndrome Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 241001135755 Betaproteobacteria Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- HECLRDQVFMWTQS-UHFFFAOYSA-N C1=CC2C3C=CC(C3)C2C1 Chemical compound C1=CC2C3C=CC(C3)C2C1 HECLRDQVFMWTQS-UHFFFAOYSA-N 0.000 description 1
- AUZFRUHVDNDVJI-UHFFFAOYSA-N CC(=O)C(C(C)=O)C(C)=O Chemical compound CC(=O)C(C(C)=O)C(C)=O AUZFRUHVDNDVJI-UHFFFAOYSA-N 0.000 description 1
- FEXQDZTYJVXMOS-UHFFFAOYSA-N CC(C)OC(=O)C1=CC=CC=C1 Chemical compound CC(C)OC(=O)C1=CC=CC=C1 FEXQDZTYJVXMOS-UHFFFAOYSA-N 0.000 description 1
- HYOWVAAEQCNGLE-UHFFFAOYSA-N CC(N)(CC1=CC=CC=C1)C(=O)O Chemical compound CC(N)(CC1=CC=CC=C1)C(=O)O HYOWVAAEQCNGLE-UHFFFAOYSA-N 0.000 description 1
- LHXDLQBQYFFVNW-OIBJUYFYSA-N CC1(C)C(=O)[C@]2(C)CC[C@H]1C2 Chemical compound CC1(C)C(=O)[C@]2(C)CC[C@H]1C2 LHXDLQBQYFFVNW-OIBJUYFYSA-N 0.000 description 1
- RGDQRXPEZUNWHX-UHFFFAOYSA-O CC1=C(N)[NH+]=CC=C1 Chemical compound CC1=C(N)[NH+]=CC=C1 RGDQRXPEZUNWHX-UHFFFAOYSA-O 0.000 description 1
- AKOVMBAFZSPEQU-AATRIKPKSA-N CCC/C=C(\C)C(=O)O Chemical compound CCC/C=C(\C)C(=O)O AKOVMBAFZSPEQU-AATRIKPKSA-N 0.000 description 1
- NVBVKZMSPFUZRG-UHFFFAOYSA-N CCC1=CC=C(C2=CC=CC=C2C#N)C=C1 Chemical compound CCC1=CC=C(C2=CC=CC=C2C#N)C=C1 NVBVKZMSPFUZRG-UHFFFAOYSA-N 0.000 description 1
- 101150050425 CCC2 gene Proteins 0.000 description 1
- CLJMMQGDJNYDER-UHFFFAOYSA-O CCCC([NH3+])CCC Chemical compound CCCC([NH3+])CCC CLJMMQGDJNYDER-UHFFFAOYSA-O 0.000 description 1
- ATZHGRNFEFVDDJ-UHFFFAOYSA-N CCCC1=CC=C(C(=O)O)C=C1 Chemical compound CCCC1=CC=C(C(=O)O)C=C1 ATZHGRNFEFVDDJ-UHFFFAOYSA-N 0.000 description 1
- XNCNNDVCAUWAIT-UHFFFAOYSA-N CCCCCCC(=O)OC Chemical compound CCCCCCC(=O)OC XNCNNDVCAUWAIT-UHFFFAOYSA-N 0.000 description 1
- XLBVNMSMFQMKEY-UHFFFAOYSA-N CNC(CCC(=O)O)C(=O)O Chemical compound CNC(CCC(=O)O)C(=O)O XLBVNMSMFQMKEY-UHFFFAOYSA-N 0.000 description 1
- PFDUUKDQEHURQC-UHFFFAOYSA-N COC1=C(O)C=CC(CC(N)C(=O)O)=C1 Chemical compound COC1=C(O)C=CC(CC(N)C(=O)O)=C1 PFDUUKDQEHURQC-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000021309 Germ cell tumor Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- VBHCPGFCIQDXGZ-BIBSGERRSA-N O=C=N[C@]12C[C@H]3C[C@H](C[C@H](C3)C1)C2 Chemical compound O=C=N[C@]12C[C@H]3C[C@H](C[C@H](C3)C1)C2 VBHCPGFCIQDXGZ-BIBSGERRSA-N 0.000 description 1
- HLRVAICAWRMJPJ-UHFFFAOYSA-N OCC1=C2CC=CC2=CC=C1 Chemical compound OCC1=C2CC=CC2=CC=C1 HLRVAICAWRMJPJ-UHFFFAOYSA-N 0.000 description 1
- QOBASENDLSYOKH-UHFFFAOYSA-O OCC[NH2+]CC1=CN=CC=C1 Chemical compound OCC[NH2+]CC1=CN=CC=C1 QOBASENDLSYOKH-UHFFFAOYSA-O 0.000 description 1
- XPZYBFOYRKOKPL-KVSKUHBBSA-N O[C@H]1[C@H]2CC[C@@H]1CNC2 Chemical compound O[C@H]1[C@H]2CC[C@@H]1CNC2 XPZYBFOYRKOKPL-KVSKUHBBSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 241001664319 Sporosarcina newyorkensis Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- ULGHUDXDTMIEAM-VIFPVBQESA-O [H][C@@](C)([NH3+])C1=C(C)C=CC(C)=C1 Chemical compound [H][C@@](C)([NH3+])C1=C(C)C=CC(C)=C1 ULGHUDXDTMIEAM-VIFPVBQESA-O 0.000 description 1
- NEDLLNIZNWRDMG-DZSWIPIPSA-N [H][C@@]1(C(=O)O)O[C@]1(CC(=O)O)C(=O)O Chemical compound [H][C@@]1(C(=O)O)O[C@]1(CC(=O)O)C(=O)O NEDLLNIZNWRDMG-DZSWIPIPSA-N 0.000 description 1
- JUTDHSGANMHVIC-JTQLQIEISA-O [H][C@@]1(C2=CC=CC=C2)CCC[NH2+]1 Chemical compound [H][C@@]1(C2=CC=CC=C2)CCC[NH2+]1 JUTDHSGANMHVIC-JTQLQIEISA-O 0.000 description 1
- JHNURUNMNRSGRO-SSDOTTSWSA-O [H][C@@]1(C[NH3+])COC2=CC=CC=C2O1 Chemical compound [H][C@@]1(C[NH3+])COC2=CC=CC=C2O1 JHNURUNMNRSGRO-SSDOTTSWSA-O 0.000 description 1
- WCIQNYOXLZQQMU-SECBINFHSA-N [H][C@](C)(OC(=O)CC)C1=CC=CC=C1 Chemical compound [H][C@](C)(OC(=O)CC)C1=CC=CC=C1 WCIQNYOXLZQQMU-SECBINFHSA-N 0.000 description 1
- DXNKJRKPVQVDJW-RITPCOANSA-O [H][C@]1([NH3+])CCCC[C@@]1([H])C(N)=O Chemical compound [H][C@]1([NH3+])CCCC[C@@]1([H])C(N)=O DXNKJRKPVQVDJW-RITPCOANSA-O 0.000 description 1
- VLLNJDMHDJRNFK-CHIWXEEVSA-N [H][C@]12C[C@]3([H])C[C@]([H])(C1)C[C@](O)(C2)C3 Chemical compound [H][C@]12C[C@]3([H])C[C@]([H])(C1)C[C@](O)(C2)C3 VLLNJDMHDJRNFK-CHIWXEEVSA-N 0.000 description 1
- TXQWFIVRZNOPCK-UHFFFAOYSA-O [NH3+]CC1=CC=NC=C1 Chemical compound [NH3+]CC1=CC=NC=C1 TXQWFIVRZNOPCK-UHFFFAOYSA-O 0.000 description 1
- GHKSKVKCKMGRDU-UHFFFAOYSA-P [NH3+]CCC[NH2+]CCO Chemical compound [NH3+]CCC[NH2+]CCO GHKSKVKCKMGRDU-UHFFFAOYSA-P 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000013398 bayesian method Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000029499 cancer-related condition Diseases 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000013527 convolutional neural network Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000013135 deep learning Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000000104 diagnostic biomarker Substances 0.000 description 1
- 235000021061 dietary behavior Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- DXMZNKNJOBUNRO-UHFFFAOYSA-N glycyl radical Chemical compound N[CH]C(O)=O DXMZNKNJOBUNRO-UHFFFAOYSA-N 0.000 description 1
- 239000005431 greenhouse gas Substances 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000010801 machine learning Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000008986 metabolic interaction Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100001160 nonlethal Toxicity 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 238000000513 principal component analysis Methods 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 230000011273 social behavior Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000012706 support-vector machine Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
-
- G06F19/16—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/121—Ketones acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G06F19/12—
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/30—Drug targeting using structural data; Docking or binding prediction
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
Definitions
- the disclosure generally relates to microbiology.
- the concept of drugging microbial targets can include one or more therapeutic approaches avoiding targeting human cells directly, and/or avoiding side effects derived from gene therapy; and instead targeting receptors and enzymes belonging to microbiota.
- Such approaches can avoid knocking-down the action of human enzymes by gene therapy methods, where such enzymes are not only possibly involved in the production of undesirable metabolites, but can also exert beneficial effects on the organism.
- Choline is a crucial nutrient for humans and other organisms, contributing to different roles in biological pathways as cell membrane function, methyl transfer events, and neurotransmission.
- TMA trimethylamine
- CutC choline trimethylamine-lyase
- Gut bacteria and/or other suitable microorganisms from any suitable body sites can play a critical role in triggering and progression of some diseases.
- Human gut microbiota has been described as producing TMA from choline; a process that is exclusively found in microbes. Choline degradation is the major source of TMA formation within the intestines.
- gut bacteria diet can have an incidence on the production of TMA and its derivative product trimethylamine-N-oxide (TMAO).
- TMAO trimethylamine-N-oxide
- TMA metabolite which is often obtained from meat, egg (e.g., egg yolk, etc.), fat-rich food, and/or dairy products is absorbed and converted to TMAO in the liver by the action of the human Flavin-containing monooxygenase 3 (FMO3) enzyme.
- FMO3 human Flavin-containing monooxygenase 3
- TMAO is a metabolite that has been associated with a high risk of cardiovascular and renal diseases, and additionally, high levels of TMAO produced from choline can trigger atherosclerosis in mice.
- Two main TMA synthesis pathways have been described in bacteria, one using choline as a substrate (CutC/CutD complex) and the other one using L-carnitine (the two-component Rieske-type oxygenase/reductase CntA/B).
- CntA/B the two-component Rieske-type oxygenase/reductase
- the pathway uses choline as a substrate (CutC/CutD complex).
- TMA is absorbed and is converted in the liver to TMAO by the action of the FMO3 enzyme.
- FMO3 participates in host-gut microbiota metabolic interactions.
- TMA hepatic inflammation and/or trimethylaminuria
- FIG. 1 includes a flowchart representation of variations of an embodiment of a method
- FIG. 2 includes a flowchart representation of variations of an embodiment of a method
- FIG. 3 includes a graphical representation of variations of an embodiment of a method.
- embodiments of a method 100 can include administering, to a patient with one or more conditions (e.g., one or more conditions associated with the at least one of TMA, TMAO, and/or derivatives thereof; etc.), a therapeutically effective amount of a compound (e.g., drug; etc.) for affecting (e.g., inhibiting; etc.) one or more targets Silo (e.g., CutC enzymes; Rieske-type oxygenase (CntA) enzymes; other enzymes; proteins; other biological targets; non-biological targets; enzymes associated with at least one of TMA, TMAO, and/or derivatives thereof; etc.) associated with microorganisms from at least one taxon from a set of microorganism taxa (e.g., from at least one of Firmicutes (
- a method 100 (e.g., for treating a patient with one or more conditions associated with at least one of TMA, TMAO, and/or derivatives thereof; etc.) can include administering, to the patient with the one or more conditions, a therapeutically effective amount of a compound for inhibiting CutC enzymes of microorganisms from at least one of Firmicutes (phylum) and Proteobacteria (phylum), where the compound (e.g., including one or more constituents, such as any suitable combination of constituents; etc.) includes at least one of: 2-Ethyl-1-butanol; (2R)-3,3-Dimethyl-1,2-butanediol; (2S)-3,3-Dimethyl-1,2-butanediol; (2S)-4-Methyl-2-pentanol; (2S)-3-Methyl-2-butanol; (2R)-4-Methyl-2-pentanol; (2R)-3-Methyl-2
- a method 100 (e.g., for treating a patient with one or more conditions associated with at least one of TMA, TMAO, and/or derivatives thereof; etc.) can include administering, to the patient with the one or more conditions, a therapeutically effective amount of a compound for inhibiting CntA enzymes of microorganisms from at least one of Firmicutes (phylum) and Proteobacteria (phylum), where the compound (e.g., including one or more constituents, such as any suitable combination of constituents; etc.) includes at least one of: N-Methylglutamic acid; 4-(1-Pyrrolidinyl)butanoic acid; 4-Methyl-4-piperidinecarboxylic acid; Isonipecotic acid; N-propylbenzene; N-Ethyl-2-pyridinamine; (4R)-4-Amino-1-propyl-2-pyrrolidinone; 2,5-Diaminotoluene;
- embodiments of the method 100 can include determining one or more representative sequences (e.g., nucleic acid sequence; amino acid sequence; etc.) of one or more targets (e.g., CutC enzymes; CntA enzymes; other enzymes; proteins; other biological targets; non-biological targets; enzymes associated with at least one of TMA, TMAO, and/or derivatives thereof; etc.) S 120 , such as where the one or more representative sequences are representative of one or more sets of sequences of the one or more targets for at least one taxon of a set of microorganism taxa (e.g., a representative sequence representative of a plurality of sequences of the target from a plurality of different taxa, such as from Firmicutes (phylum) and Proteobacteri
- targets e.g., CutC enzymes; CntA enzymes; other enzymes; proteins; other biological targets; non-biological targets; enzymes associated with at least one of TMA, TMAO, and/or derivatives thereof
- Embodiments of the method 100 and/or system 200 can function to diagnose and/or treat one or more patients with one or more conditions associated with at least one of TMA, TMAO, and/or derivatives thereof, such as by using and/or administering (and/or other suitable provision and/or promotion) of one or more compounds affecting one or more targets (e.g., inhibiting CutC enzymes; inhibiting CntA enzymes; etc.) associated with the one or more conditions (e.g., correlated with, causative; etc.) and/or associated with microorganisms from at least one taxon from a set of taxa (e.g., from at least one of Firmicutes (phylum) and Proteobacteria (phylum); etc.).
- targets e.g., inhibiting CutC enzymes; inhibiting CntA enzymes; etc.
- microorganisms from at least one taxon from a set of taxa e.g., from at least one of Firmicutes (phylum)
- embodiments of the method 100 and/or system 200 can function to identify one or more compounds that can be administered for treating one or more patients with one or more conditions (e.g., associated with at least one of TMA, TMAO, and/or derivatives thereof; etc.).
- one or more conditions e.g., associated with at least one of TMA, TMAO, and/or derivatives thereof; etc.
- the method 100 can screen libraries of compounds (e.g., including any suitable number of compounds; etc.), based on molecular docking simulations, for identifying compounds (e.g., drugs; etc.) that can bind the active site of one or more targets (e.g., CutC enzymes; CntA enzymes; etc.) from microorganisms (e.g., from Firmicutes (phylum) and/or Proteobacteria (phylum); etc.) and associated with TMA, TMAO, and/or derivatives thereof, such as for identifying compounds with therapeutic effects (e.g., by inhibiting production of TMA; TMAO; derivatives thereof; etc.) on conditions associated with TMA, TMAO, and/or derivatives thereof.
- the method 100 can overcome side effects and/or complications associated with inhibiting FMO3 enzyme, such as by selectively inhibiting pathways producing TMA, such as CutC/CutD and/or CntA/CntB.
- Conditions preferably include conditions associated with characterizations and/or therapies for one or more microorganism-related conditions associated with at least one of TMA, TMAO, and/or derivatives thereof (e.g., conditions triggerable, caused by, correlated with, and/or otherwise associated with one or more of TMA, TMAO, and/or derivatives thereof, such as a high amounts of TMA, TMAO, and/or derivatives thereof; etc.).
- Conditions associated with at least one of TMA, TMAO, and/or derivatives thereof can include any one or more of: cardiovascular conditions (e.g., atherosclerosis; severe heart failure; coronary heart disease; inflammatory heart disease; valvular heart disease; obesity; stroke; thrombosis, platelet responsiveness, etc.); renal conditions (e.g., renal failure; chronic kidney disease; polycystic kidney disease; glomerulonephritis; IgA nephropathy; nephritis; nephrotic syndrome; lupus; kidney cancer; rare kidney diseases; etc.); metabolic-related conditions (e.g., trimethylaminuria (TMAU); etc.); nutrition-related conditions (e.g., weight-related conditions such as weight-loss conditions; blood sugar-related conditions such as high blood sugar-related conditions; allergy-related conditions such as allergies and/or intolerance associated with wheat, gluten, dairy, soy, peanut, shellfish, tree nut, egg; etc.).
- cardiovascular conditions e
- conditions can include any one or more of: gastrointestinal-related conditions (e.g., irritable bowel syndrome, inflammatory bowel disease, ulcerative colitis, celiac disease, Crohn's disease, bloating, hemorrhoidal disease, constipation, reflux, bloody stool, diarrhea, etc.); skin-related conditions (e.g., acne, dermatomyositis, eczema, rosacea, dry skin, psoriasis, dandruff, photosensitivity, rough skin, itching, flaking, scaling, peeling, fine lines or cracks, gray skin in individuals with dark skin, redness, deep cracks such as cracks that can bleed and lead to infections, itching and scaling of the skin in the scalp, oily skin such as irritated oily skin, skin sensitivity to products such as hair care products, imbalance in scalp microbiome, etc.); locomotor-related conditions (e.g., gout, rheumatoid arthritis, osteoarthriti
- conditions can include one or more human behavior conditions which can include any one or more of: caffeine consumption, alcohol consumption, other food item consumption, dietary supplement consumption, probiotic-related behaviors (e.g., consumption, avoidance, etc.), other dietary behaviors, habituary behaviors (e.g., smoking; exercise conditions such as low, moderate, and/or extreme exercise conditions; etc.), menopause, other biological processes, social behavior, other behaviors, and/or any other suitable human behavior conditions.
- probiotic-related behaviors e.g., consumption, avoidance, etc.
- other dietary behaviors e.g., eating, exercise conditions such as low, moderate, and/or extreme exercise conditions; etc.
- habituary behaviors e.g., smoking; exercise conditions such as low, moderate, and/or extreme exercise conditions; etc.
- menopause e.g., other biological processes, social behavior, other behaviors, and/or any other suitable human behavior conditions.
- Conditions can include one or more of: diseases, symptoms, causes (e.g., triggers, etc.), disorders, associated risk (e.g., propensity scores, etc.), associated severity, behaviors (e.g., caffeine consumption, habits, diets, etc.), and/or any other suitable aspects associated with conditions.
- Conditions can be associated with any suitable phenotypes (e.g., phenotypes measurable for a human, animal, plant, fungi body, etc.).
- the condition can include at least one of: a cardiovascular condition (e.g., atherosclerosis; etc.), a renal condition (e.g., renal failure; etc.), a metabolic-related condition (e.g., trimethylaminuria; etc.), and/or a nutrition-related condition (e.g., a weight-related condition; a high blood sugar-related condition; etc.); where the condition can be associated with at least one of TMA, TMAO, and/or derivatives thereof; and where administering to one or more patients can include administering, to the one or more patients with the one or more conditions (e.g., etc.;), a therapeutically effective amount of one or more compounds (e.g., any suitable compounds in and/or including any suitable combination of compounds from Tables 1-8; etc.) for inhibiting one or more enzymes (e.g., CutC enzymes; CntA enzymes; enzymes associated with the at least one of TMA,
- a cardiovascular condition e.g., atherosclerosis;
- data described herein can be associated with any suitable temporal indicators (e.g., seconds, minutes, hours, days, weeks, time periods, time points, timestamps, etc.) including one or more: temporal indicators indicating when the data was collected, determined, transmitted, received, and/or otherwise processed; temporal indicators providing context to content described by the data; changes in temporal indicators (e.g., data over time; change in data; data patterns; data trends; data extrapolation and/or other prediction; etc.); and/or any other suitable indicators related to time.
- temporal indicators e.g., seconds, minutes, hours, days, weeks, time periods, time points, timestamps, etc.
- temporal indicators e.g., seconds, minutes, hours, days, weeks, time periods, time points, timestamps, etc.
- temporal indicators e.g., seconds, minutes, hours, days, weeks, time periods, time points, timestamps, etc.
- temporal indicators e.g., seconds, minutes, hours, days, weeks
- parameters, metrics, inputs, outputs, and/or other suitable data can be associated with value types including any one or more of: scores (e.g., binding parameters; interaction parameters; etc.), binary values (e.g., presence of a target within a microorganism taxon; etc.), classifications (e.g., taxon classifications; etc.), confidence levels, identifiers (e.g., compound identifiers; etc.), values along a spectrum, and/or any other suitable types of values.
- scores e.g., binding parameters; interaction parameters; etc.
- binary values e.g., presence of a target within a microorganism taxon; etc.
- classifications e.g., taxon classifications; etc.
- confidence levels e.g., confidence levels
- identifiers e.g., compound identifiers; etc.
- Any suitable types of data described herein can be used as inputs (e.g., for different models described herein; for portions of embodiments the method 100 ; etc.), generated as outputs (e.g., of models), and/or manipulated in any suitable manner for any suitable components associated with embodiments of the method 100 and/or system 200 .
- One or more instances and/or portions of embodiments of the method 100 and/or processes described herein can be performed asynchronously (e.g., sequentially), concurrently (e.g., in parallel; concurrently on different threads for parallel computing to improve system processing ability for screening and/or otherwise determining compounds; etc.), in temporal relation to a trigger event (e.g., performance of a portion of the method 100 ), and/or in any other suitable order at any suitable time and frequency by and/or using one or more instances of embodiments of the system 200 , components, and/or entities described herein.
- Embodiments of the system 200 can include any one or more of: compounds and/or pharmaceutically acceptable forms thereof, and/or salts (e.g., pharmaceutically acceptable salts; etc.) thereof; computing systems (e.g., for identifying one or more compounds; etc.); sample handling networks; sequencing systems; and/or any other suitable components.
- the system 200 and/or portions of the system 200 can entirely or partially be executed by, hosted on, communicate with, and/or otherwise include: a remote computing system (e.g., a server, at least one networked computing system, stateless, stateful; etc.), a local computing system, a user device (e.g., mobile phone device, other mobile device, personal computing device, tablet, wearable, head-mounted wearable computing device, wrist-mounted wearable computing device, etc.), a care provider device, databases, application programming interfaces (APIs) (e.g., for accessing data described herein, etc.) and/or any suitable components.
- a remote computing system e.g., a server, at least one networked computing system, stateless, stateful; etc.
- a local computing system e.g., a user device (e.g., mobile phone device, other mobile device, personal computing device, tablet, wearable, head-mounted wearable computing device, wrist-mounted wearable computing device, etc.)
- APIs
- Communication by and/or between any components of the system 200 can include wireless communication (e.g., WiFi, Bluetooth, radiofrequency, Zigbee, Z-wave, etc.), wired communication, and/or any other suitable types of communication.
- the components of the system 200 can be physically and/or logically integrated in any manner (e.g., with any suitable distributions of functionality across the components, such as in relation to portions of embodiments of the method 100 ; etc.).
- Portions of embodiments of the method 100 and/or system 200 can be performed by any one or more of: first parties; third parties; car providers (e.g., doctors; nurses; etc.); lab technicians; users; compound providers; and/or any suitable entities.
- car providers e.g., doctors; nurses; etc.
- lab technicians e.g., doctors; nurses; etc.
- users e.g., doctors; nurses; etc.
- compound providers e.g., etc.
- embodiments of the method 100 and/or system 200 can be configured in any suitable manner.
- Embodiments of the method 100 can include administering (and/or other suitable provision of; promotion of; etc.) administering one or more compounds (e.g., a therapeutically effective amount of the one or more compounds; etc.) to one or more patients with one or more conditions Silo (e.g., one or more conditions associated with the at least one of TMA, TMAO, and/or derivatives thereof; etc.), which can function to facilitate treatment of one or more patients.
- one or more compounds e.g., a therapeutically effective amount of the one or more compounds; etc.
- Silo e.g., one or more conditions associated with the at least one of TMA, TMAO, and/or derivatives thereof; etc.
- a therapeutically effective amount of the one or more compounds is preferably administered, but any suitable amounts of the one or more compounds can be administered.
- the compounds preferably affect (e.g., inhibiting; etc.) one or more targets (e.g., CutC enzymes; CntA enzymes; etc.) associated with one or more conditions associated at least one of TMA, TMAO, and/or derivatives thereof, such as for inhibiting production of TMA, TMAO, and/or derivatives thereof (e.g., for preventing, treating, and/or reducing the effect of conditions associated with TMA, TMAO, and/or derivatives thereof; etc.).
- targets e.g., CutC enzymes; CntA enzymes; etc.
- the compounds can otherwise affect (e.g., activate, upregulate, downregulate, bind; etc.) the one or more targets, and/or the targets can be associated with any suitable conditions.
- Compounds can include any suitable combination of (e.g., one or more; combinations; individual molecules and/or compounds; etc.), derivative of, pharmaceutically acceptable form of, and/or any suitable form of compounds included in Tables 1-8.
- Compounds can include any suitable pharmaceutically acceptable forms of the compounds, which can include any one or more of: derivatives; pharmaceutically deliverable forms; forms with carriers, agents, supplemental components; salts; and/or any suitable acceptable forms.
- Compounds can include any suitable salts (e.g., pharmaceutically acceptable salts; etc.) thereof, and/or any suitable forms of the compounds.
- Targets can include any one or more of: CutC enzymes; CntA enzymes; CutD enzymes; CntB enzymes; other enzymes (e.g., associated with at least one of TMA, TMAO, and/or derivatives thereof; etc.); proteins; target markers (e.g., biomarkers; etc.); targets of interest; known or identified targets; unknown or previously unidentified targets; genetic targets; sequences (e.g., amino acid sequences; nucleic acid sequences; etc.); compounds; peptides; carbohydrates; lipids; nucleic acids; cells (e.g., whole cells, etc.); metabolites; natural products; diagnostic biomarkers; prognostic biomarkers; predictive biomarkers; other molecular biomarkers; biological targets; non-biological targets; other molecules (e.g., associated with
- Targets are preferably associated with microorganisms (e.g., are from the microorganisms; are produced by the microorganisms; have been found in relation to the microorganisms; are present in the microorganisms; are encoded by genetic sequences, amino acid sequences, and/or other suitable sequences of the microorganisms; etc.) from at least one taxon from a set of microorganism taxa (e.g., from at least one of Firmicutes (phylum) and Proteobacteria (phylum); etc.).
- a set of microorganism taxa e.g., from at least one of Firmicutes (phylum) and Proteobacteria (phylum); etc.
- targets can be associated with microorganisms from any suitable microorganism taxa (e.g., domain, kingdom, phylum, class, order, family, genus, species; etc.) and/or microorganisms associated with any suitable body site including any one or more of gut, skin, nose, mouth, genitals, and/or any suitable body site.
- Administering a compound can include any one or more of providing, promoting, and/or otherwise administering a compound.
- Administering one or more compounds can include administering (e.g., a therapeutically effective amount of; etc.) one or more compounds for inhibiting (and/or otherwise affecting) CutC enzymes, such as CutC enzymes of microorganisms from at least one of Firmicutes (phylum), Proteobacteria (phylum), and/or other suitable taxa.
- administering e.g., a therapeutically effective amount of; etc.
- CutC enzymes such as CutC enzymes of microorganisms from at least one of Firmicutes (phylum), Proteobacteria (phylum), and/or other suitable taxa.
- Compounds for inhibiting (and/or otherwise affecting) CutC enzymes can include one or more 3,3-dimethyl-1-butanol (DMB) analogues (e.g., binding with equal or higher affinity to CutC enzymes than DMB, such as for CutC enzymes belonging to Proteobacteria and/or Firmicutes; etc.).
- DMB 3,3-dimethyl-1-butanol
- DMB can inhibit TMA formation by CutC enzymes (e.g., derived from cultured microbes in a non-lethal way, such as not an antibiotic); can reduce TMAO levels (e.g., in animals with a high choline or carnitine diet; etc.); and/or can bind the active site of CutC enzymes (e.g., with higher affinity than choline, thereby exerting competitive inhibition; etc.).
- CutC enzymes e.g., derived from cultured microbes in a non-lethal way, such as not an antibiotic
- TMAO levels e.g., in animals with a high choline or carnitine diet; etc.
- DMB analogues can include any one or more compounds included in Table 1.
- administering to the patient with the one or more conditions can include administering, to the patient with the one or more conditions, a therapeutically effective amount of a compound including a 3,3-dimethyl-1-butanol (DMB) analogue including at least one (e.g., any one or more; etc.) of: 2-Ethyl-1-butanol; (2R)-3,3-Dimethyl-1,2-butanediol; (2S)-3,3-Dimethyl-1,2-butanediol; (2S)-4-Methyl-2-pentanol; (2S)-3-Methyl-2-butanol; (2R)-4-Methyl-2-pentanol; (2R)-3-Methyl-2-butanol; (2S)-2-Pentanol; (2S)-2-Methyl-1,4-butanediol; 2-Methyl-2,4-butanediol; Trimethylol
- Compounds for inhibiting (and/or otherwise affecting) CutC enzymes can include one or more compounds for inhibiting the CutC enzymes of microorganisms from Firmicutes (phylum), such as where the one or more compounds (and/or compounds generally) can include any one or more compounds included in Table 2 (e.g., where the compounds can include specificity for CutC enzymes from microorganisms from Firmicutes; where the compounds do not bind or bind with lower affinity to CutC enzymes from microorganisms from Proteobacteria; where each compound can be representative of a subset of molecules exerting the same binding energy and such as with similar structure to the compound; where the compounds can include higher affinity, as indicated by the binding energy values, than choline or DMB, to the CutC enzymes; etc.).
- Table 2 e.g., where the compounds can include specificity for CutC enzymes from microorganisms from Firmicutes; where the compounds do not bind or bind with lower affinity to CutC enzymes from microorgan
- administering to the patient with the one or more conditions can include administering, to the patient with the one or more conditions, a therapeutically effective amount of a compound for inhibiting the CutC enzymes of the microorganisms from Firmicutes (phylum), where the compound includes at least one (e.g., any one or more; etc.) of: 3-(4-Methoxyphenyl)propanal; 1-(3-Pyridinyl)-2-propanamine; 2-[(2R)-2-Butanyl]phenol; 4-Propylbenzoic acid; (2S)-1-(Benzyloxy)-2-propanol; Methyl 3-(4-hydroxyphenyl)propanoate; ⁇ -Methylphenylalanine; 2,2-Dimethyl-1-phenyl-1-propanol; Methyl (2R)-hydroxy(phenyl)acetate; (2S)-2-Phenylpyrrolidinium; 4-Methyl-3-phenyl-1,2-o
- Compounds for inhibiting (and/or otherwise affecting) CutC enzymes can include one or more compounds for inhibiting the CutC enzymes of microorganisms from Proteobacteria (phylum), such as where the one or more compounds (and/or compounds generally) can include any one or more compounds included in Table 3 (e.g., where the compounds can include specificity for CutC enzymes from microorganisms from Proteobacteria; where the compounds do not bind or bind with lower affinity to CutC enzymes from microorganisms from Firmicutes; where each compound can be representative of a subset of molecules exerting the same binding energy and such as with similar structure to the compound; where the compounds can include higher affinity, as indicated by the binding energy values, than choline or DMB, to the CutC enzymes; etc.).
- Table 3 e.g., where the compounds can include specificity for CutC enzymes from microorganisms from Proteobacteria; where the compounds do not bind or bind with lower affinity to Cut
- administering to the patient with the one or more conditions can include administering, to the patient with the one or more conditions, a therapeutically effective amount of a compound for inhibiting the CutC enzymes of the microorganisms from Proteobacteria (phylum), where the compound includes at least one (e.g., any one or more; etc.) of: N-(2-Hydroxyethyl)-1,3-propanediaminium; 3-Methoxy-3-methylbutanol; 4-Pyridinylmethanaminium; N-Methyl-3-pyridinamine; 2-Methoxypyridine; 5-Methyl-3-pyridinamine; 1-(4-Methyl-3-pyridinyl)methanamine; Mesitylene; (E)-Benzaldoxime’ (3R)-2,2,4-Trimethyl-1,3-pentanediol; (1R,4R)-2-Azabicyclo[2.2.1]hept-2-ylacetic acid; 3-ACE
- Compounds for inhibiting (and/or otherwise affecting) CutC enzymes can include one or more compounds for inhibiting the CutC enzymes of microorganisms from Firmicutes (phylum) and Proteobacteria (phylum) (e.g., inhibiting CutC enzymes of first microorganisms from Firmicutes as well as CutC enzymes of second microorganisms from Proteobacteria, etc.), such as where the one or more compounds (and/or compounds generally) can include any one or more compounds included in Table 4 (e.g., compounds binding CutC enzymes associated with Firmicutes, and binding CutC enzymes associated with Proteobacteria; such as where the compounds can inhibit products of TMA by CutC in a set of microorganisms across different taxa, such as across Firmicutes and Proteobacteria; where each compound can be representative of a subset of molecules exerting the same binding energy and such as with similar structure to the compound; where the compounds can include higher affinity, as indicated
- administering to the patient with the one or more conditions can include administering, to the patient with the one or more conditions, a therapeutically effective amount of a compound for inhibiting the CutC enzymes of the microorganisms from Firmicutes (phylum) and Proteobacteria (phylum), where the compound includes at least one (e.g., any one or more; etc.) of: Methyl 4-methyl-4-piperidinecarboxylate; Methyl heptanoate; 3-Methylpyridazine; 4,5-Dimethyl-1,2-oxazol-3-amine; 2-(2-Hydroxyethoxy)phenol; 2-Hydroxy-N-(3-pyridinylmethyl)ethanaminium; 3-Phenyl-1-propanol; (2R)-6-Methyl-2-heptanol; 2-Phenoxyacetohydrazide; N-Hydroxyoctanamid; Cyclobutanecarb
- compounds including different binding affinities (and/or other suitable interaction parameters) to CutC enzymes depending on the association of the CutC enzyme to a given taxon can enable different applications, such as where a compound with high affinity can exert an irreversible inhibition on the CutC enzyme.
- compounds for inhibiting CutC enzymes of microorganisms from Firmicutes (phylum) and Proteobacteria (phylum) can be configured in any suitable manner, and administering such compounds can be performed in any suitable manner (e.g., for affecting any suitable targets).
- Administering one or more compounds can include administering (e.g., a therapeutically effective amount of; etc.) one or more compounds for inhibiting (and/or otherwise affecting) CntA enzymes, such as CntA enzymes of microorganisms from at least one of Firmicutes (phylum), Proteobacteria (phylum), and/or other suitable taxa.
- administering e.g., a therapeutically effective amount of; etc.
- one or more compounds for inhibiting (and/or otherwise affecting) CntA enzymes such as CntA enzymes of microorganisms from at least one of Firmicutes (phylum), Proteobacteria (phylum), and/or other suitable taxa.
- L-carnitine e.g., a substrate for CntA enzymes; etc.
- L-carnitine can facilitate the production of TMA, TMAO, and/or derivatives thereof through binding to an active site on CntA enzymes
- L-carnitine can be associated with (e.g., cause, correlated with, influence, etc.) metabolic-related conditions, nutritional-related conditions (e.g., weight-related conditions; high blood sugar-related conditions; etc.), and/or other suitable conditions, such as where compounds inhibiting (and/or otherwise affecting) CntA enzymes can decrease the effect of L-carnitine and/or CntA enzymes in relation to the one or more conditions.
- Compounds for inhibiting (and/or otherwise affecting) CntA enzymes can include one or more L-carnitine analogues (e.g., binding with equal or higher affinity to CntA enzymes than L-carnitine, such as for CntA enzymes belonging to Proteobacteria and/or Firmicutes; etc.).
- L-carnitine analogues e.g., binding with equal or higher affinity to CntA enzymes than L-carnitine, such as for CntA enzymes belonging to Proteobacteria and/or Firmicutes; etc.
- the L-carnitine analogues and/or other suitable compounds can bind to CntA enzymes to competitively inhibit the binding of L-carnitine to the CntA enzymes (e.g., where the substrate and inhibitor cannot bind the active site simultaneously; where the competitive inhibition can facilitate decrease in production of TMA, TMAO, and/or derivatives thereof; etc.).
- L-carnitine analogues (and/or compounds generally) can include any one or more compounds included in Table 5. Table 5.
- administering to the patient with the one or more conditions can include administering, to the patient with the one or more conditions, a therapeutically effective amount of a compound including an L-carnitine analogue including at least one (e.g., any one or more; etc.) of: N-Methylglutamic acid; 4-(1-Pyrrolidinyl)butanoic acid; 4-Methyl-4-piperidinecarboxylic acid; Isonipecotic acid; and pharmaceutically acceptable forms thereof (e.g., derivatives thereof; pharmaceutically deliverable forms thereof; etc.); and/or salts (e.g., pharmaceutically acceptable salts; etc.) thereof.
- compounds including an L-carnitine analogue can be configured in any suitable manner, and administering such compounds can be performed in any suitable manner (e.g., for affecting any suitable targets).
- Compounds for inhibiting (and/or otherwise affecting) CntA enzymes can include one or more compounds for inhibiting the CntA enzymes of microorganisms from Firmicutes (phylum), such as where the one or more compounds (and/or compounds generally) can include any one or more compounds included in Table 6 (e.g., where the compounds can include specificity for CntA enzymes from microorganisms from Firmicutes; where the compounds do not bind or bind with lower affinity to CntA enzymes from microorganisms from Proteobacteria; where each compound can be representative of a subset of molecules exerting the same binding energy and such as with similar structure to the compound; where the compounds can include higher affinity, as indicated by the binding energy values, than L-carnitine, to the CntA enzymes; etc.).
- Table 6 e.g., where the compounds can include specificity for CntA enzymes from microorganisms from Firmicutes; where the compounds do not bind or bind
- administering to the patient with the one or more conditions can include administering, to the patient with the one or more conditions, a therapeutically effective amount of a compound for inhibiting the CntA enzymes of the microorganisms from Firmicutes (phylum), where the compound includes at least one (e.g., any one or more; etc.) of: N-propylbenzene; N-Ethyl-2-pyridinamine; (4R)-4-Amino-1-propyl-2-pyrrolidinone; 2,5-Diaminotoluene; Ethyl phenyl ether; Phenylcyanate; 1-(2-Cyclopenten-1-yl)acetone; 2-Amino-3-methylpyridinium; E-pyridine-3-aldoxime; N-Cyclohexylformamide; 2-Methyl-2-hexenoic acid; 4-Heptanaminium; and pharmaceutically acceptable forms thereof (e.g., derivatives thereof; pharmaceutically deliverable forms
- Compounds for inhibiting (and/or otherwise affecting) CntA enzymes can include one or more compounds for inhibiting the CntA enzymes of microorganisms from Proteobacteria (phylum), such as where the one or more compounds (and/or compounds generally) can include any one or more compounds included in Table 7 (e.g., where the compounds can include specificity for CntA enzymes from microorganisms from Proteobacteria; where the compounds do not bind or bind with lower affinity to CntA enzymes from microorganisms from Firmicutes; where each compound can be representative of a subset of molecules exerting the same binding energy and such as with similar structure to the compound; where the compounds can include higher affinity, as indicated by the binding energy values, than L-carnitine, to the CntA enzymes; etc.).
- Table 7 e.g., where the compounds can include specificity for CntA enzymes from microorganisms from Proteobacteria; where the compounds do
- administering to the patient with the one or more conditions can include administering, to the patient with the one or more conditions, a therapeutically effective amount of a compound for inhibiting the CntA enzymes of the microorganisms from Proteobacteria (phylum), where the compound includes at least one (e.g., any one or more; etc.) of: 3,4-Anhydro-3-carboxy-2-deoxy-L-threo-pentaric acid; 2,2′-[(2-Hydroxyethyl)imino]diacetic acid; 1H-Tetrazol-5-ylacetic acid; Diacetylacetone; (2S)-2-Acetoxypropanoic acid; and pharmaceutically acceptable forms thereof (e.g., derivatives thereof; pharmaceutically deliverable forms thereof; etc.); and/or salts (e.g., pharmaceutically acceptable salts; etc.) thereof.
- compounds for inhibiting CntA enzymes of microorganisms from Proteobacteria include administering
- Compounds for inhibiting (and/or otherwise affecting) CntA enzymes can include one or more compounds for inhibiting the CntA enzymes of microorganisms from Firmicutes (phylum) and Proteobacteria (phylum) (e.g., inhibiting CntA enzymes of first microorganisms from Firmicutes as well as CntA enzymes of second microorganisms from Proteobacteria, etc.), such as where the one or more compounds (and/or compounds generally) can include any one or more compounds included in Table 8 (e.g., compounds binding CntA enzymes associated with Firmicutes, and binding CntA enzymes associated with Proteobacteria; such as where the compounds can inhibit products of TMA by CntA in a set of microorganisms across different taxa, such as across Firmicutes and Proteobacteria; where each compound can be representative of a subset of molecules exerting the same binding energy and such as with similar structure
- administering to the patient with the one or more conditions can include administering, to the patient with the one or more conditions, a therapeutically effective amount of a compound for inhibiting the CntA enzymes of the microorganisms from Firmicutes (phylum) and Proteobacteria (phylum), where the compound includes at least one (e.g., any one or more; etc.) of: 4,4′-Biphthalic anhydride; Bis(1H-benzotriazol-1-yl)methanone; 2-Anthraquinonesulfonic acid; 3-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)benzonitrile.; 2-phenylquinazolin-4-ol; 4-Amino-2-(1,3-benzothiazol-2-yl)phenol; 4-Phenyl-1(2H)-phthalazinone; 5-(1,3-Benzodioxol-5-yl)-2-
- compounds including different binding affinities (and/or other suitable interaction parameters) to CntA enzymes depending on the association of the CntA enzyme to a given taxon can enable different applications, such as where a compound with high affinity can exert an irreversible inhibition on the CntA enzyme.
- compounds for inhibiting CntA enzymes of microorganisms from Firmicutes (phylum) and Proteobacteria (phylum) can be configured in any suitable manner, and administering such compounds can be performed in any suitable manner (e.g., for affecting any suitable targets).
- compounds can be configured in any suitable manner, and administering one or more compounds Silo can be performed in any suitable manner.
- embodiments of the method 100 can include determining one or more representative sequences of one or more targets (e.g., CutC enzymes; CntA enzymes; other enzymes; proteins; other biological targets; non-biological targets; enzymes associated with at least one of TMA, TMAO, and/or derivatives thereof; etc.) S 120 , which can function to determine representative characteristics of targets for use in modeling and/or experiments for facilitating compound determination.
- targets e.g., CutC enzymes; CntA enzymes; other enzymes; proteins; other biological targets; non-biological targets; enzymes associated with at least one of TMA, TMAO, and/or derivatives thereof; etc.
- Representative sequences and/or characteristics can include any one or more of nucleic acid sequence and/or composition; amino acid sequence and/or composition; functional characteristics; structural characteristics (e.g., multi-dimensional structure; etc.); evolutionary characteristics; and/or other suitable characteristics.
- Representative sequences and/or characteristics are preferably determined for one or more targets, but can additionally or alternatively be determined for one or more of control molecules, compounds, and/or any other suitable molecules.
- representative sequences and/or characteristics can be determined for one or more enzymes, such as where the enzyme can include at least one CutC enzyme and CntA enzyme, and where the representative sequence can be representative of a set of sequences of the enzyme for at least one taxon including at least one of Firmicutes (phylum) and Proteobacteria (phylum).
- Representative sequences and/or characteristics are preferably representative for one or more taxons from a set of microorganism taxa.
- a representative sequence can be representative of a set of sequences of one or more targets (e.g., CutC enzyme, CntA enzyme, etc.) for one or more microorganism taxa (e.g., Firmicutes and/or Proteobacteria and/or other suitable taxa; etc.).
- targets e.g., CutC enzyme, CntA enzyme, etc.
- microorganism taxa e.g., Firmicutes and/or Proteobacteria and/or other suitable taxa; etc.
- determining one or more representative sequences can include: generating a sequence similarity network with target sequences (e.g., CutC enzyme sequences; CntA enzyme sequences; etc.) associated with (e.g., belonging to; of microorganisms belonging to; etc.) each taxon of the set of taxa (e.g., associated with both Firmicutes and Proteobacteria), such as in order to identify a representative target sequence for each taxon (e.g., a first representative CutC enzyme sequence for Firmicutes and a second representative CutC enzyme sequence for Proteobacteria; a first representative CntA enzyme sequence for Firmicutes and a second representative CntA enzyme sequence for Proteobacteria; etc.).
- target sequences e.g., CutC enzyme sequences; CntA enzyme sequences; etc.
- determining one or more representative sequences S 120 can be performed in any suitable manner.
- embodiments of the method 100 can include generating one or more models (e.g., protein structure models; etc.) of the one or more targets based on the one or more representative sequences of the one or more targets S 130 , which can function to model one or more targets for facilitating experiments useful in compound determinations.
- models e.g., protein structure models; etc.
- Models preferably include protein structure models (e.g., modeling enzyme targets such as CntA enzymes and/or CutC enzymes; etc.), but can additionally or alternatively include any suitable models (e.g., modeling any suitable types of targets; etc.).
- Models can include any one or more of computational models, models of any suitable number of dimensions, non-computational models, physical models, virtual reality models, augmented reality models, and/or any suitable types of models. Models can be generating using any suitable processing operations and/or artificial intelligence approaches described herein.
- Generating models is preferably based on representative sequences, such as where characteristics of the representative sequences can be used as inputs and/or parameters for model generation.
- generating models can include generating protein structure models for both the CutC enzyme from Firmicutes (e.g., Uniprot ID: CoD5P1) (e.g., based on the representative sequence for the CutC enzyme from microorganisms from Firmicutes; etc.) and CutC enzyme from Proteobacteria (e.g., Uniprot ID: B4EYG1) (e.g., based on the representative sequence for the CutC enzyme from microorganisms from Proteobacteria; etc.) using a homology modeling approach (and/or any suitable modeling approach), which can facilitate determination of 3D models (e.g., for proteins lacking crystallographic data; etc.).
- Uniprot ID: CoD5P1 e.g., based on the representative sequence for the CutC enzyme from microorganisms from Firmicutes;
- generating models can include generating protein structure models for both the CntA enzyme from Firmicutes (e.g., Uniprot ID: J3B3E2) (e.g., based on the representative sequence for the CntA enzyme from microorganisms from Firmicutes; etc.) and CntA enzyme from Proteobacteria (e.g., Uniprot ID: L1LUC3) (e.g., based on the representative sequence for the CntA enzyme from microorganisms from Proteobacteria; etc.) using a homology modeling approach (and/or any suitable modeling approach), which can facilitate determination of 3D models (e.g., for proteins lacking crystallographic data; etc.).
- CntA enzyme from Firmicutes e.g., Uniprot ID: J3B3E2
- CntA enzyme from Proteobacteria e.g., Uniprot ID: L1LUC3
- homology modeling approach and/or any suitable modeling
- generating one or more models S 130 can be performed in any suitable manner.
- embodiments of the method 100 can include determining one or more control binding parameters (and/or other suitable interaction parameters; etc.) to the one or more targets based on one or more experiments with the one or more models and one or more control molecules S 140 , which can function to determine characteristics describing interactions between one or more controls and one or more targets.
- Types of binding parameters preferably include types of binding parameters included in Tables 1-8 (e.g., binding energy values, affinity energy values, etc.), but can additionally or alternatively include association rate, dissociation rate, half-life of interaction (e.g., between receptor and peptide), binding constants, binding specificity, thermodynamics associated parameters (e.g. enthalpy, entropy, Gibbs free energy), parameters associated with number and type of binding sites (e.g., stoichiometry), parameters associated with undesired binding (e.g., self-assembly, interference with other proteins, etc.), and/or any other suitable binding parameters. include any suitable binding affinity parameters.
- Interaction parameters preferably include binding affinities, but can additionally or alternatively include any suitable parameters associated with control molecules, compounds, targets, and/or other suitable molecules, and/or associated with interactions between any combination of such molecules.
- Experiments preferably include docking simulations (e.g., docking simulations using the one or more models and simulating the binding of one or more control molecules to the one or more models, such as to the active sites of one or more of the protein structure models for CutC enzymes and/or CntA enzymes; etc.), but can additionally or alternatively include one or more of: other computational simulations (e.g., in silico, etc.); in vitro experiments, in vivo experiments, benchtop experiments, use of computational models, and/or any other suitable other experiments.
- other computational simulations e.g., in silico, etc.
- in vitro experiments e.g., in vitro experiments, in vivo experiments, benchtop experiments, use of computational models, and/or any other suitable other experiments.
- docking simulations can be performed to determine control binding parameters (e.g., binding energy values for the control molecules; etc.) for choline and DMB in relation to binding CutC enzymes of microorganisms from different taxa (e.g., Firmicutes and/or Proteobacteria; etc.), such as based on performing docking simulations with generated models of the CutC enzymes for the different taxa (e.g., a first model of the CutC enzyme from Firmicutes; a second model of the CutC enzyme from Proteobacteria; etc.) and simulating control molecule (e.g., choline and/or DMB) binding to the generated models.
- control binding parameters e.g., binding energy values for the control molecules; etc.
- cutC enzymes of microorganisms from different taxa e.g., Firmicutes and/or Proteobacteria; etc.
- generated models of the CutC enzymes for the different taxa e.g.,
- docking simulations can result in binding energy values of ⁇ 3.7 kcal/mol for choline in relation to CutC enzyme from Firmicutes; ⁇ 4.8 kcal/mol for DMB in relation to CutC enzyme from Firmicutes; ⁇ 4.1 kcal/mol for choline in relation to CutC enzyme from Proteobacteria; and ⁇ 5.2 kcal/mol for DMB in relation to CutC enzyme from Proteobacteria, such as where such binding energy values can indicate a greater affinity of binding for DMB than for choline (e.g., in the context of competitive inhibition; etc.)
- docking simulations can be performed to determine control binding parameters (e.g., binding energy values for the control molecules; etc.) for L-carnitine in relation to binding CntA enzymes of microorganisms from different taxa (e.g., Firmicutes and/or Proteobacteria; etc.), such as based on performing docking simulations with generated models of the CntA enzymes for the different taxa (e.g., a first model of the CntA enzyme from Firmicutes; a second model of the CntA enzyme from Proteobacteria; etc.) and simulating control molecule (e.g., L-carnitine; DMB; etc.) binding to the generated models.
- control binding parameters e.g., binding energy values for the control molecules; etc.
- CntA enzymes of microorganisms from different taxa e.g., Firmicutes and/or Proteobacteria; etc.
- simulating control molecule e
- docking simulations can result in binding energy values of ⁇ 4.5 kcal/mol for L-carnitine in relation to CntA enzyme from Firmicutes; ⁇ 4.8 kcal/mol for DMB in relation to CntA enzyme from Firmicutes; ⁇ 4.3 kcal/mol for L-carnitine in relation to CntA enzyme from Proteobacteria; and ⁇ 5.2 kcal/mol for DMB in relation to CntA enzyme from Proteobacteria.
- docking simulations can be performed with any suitable models in relation to any suitable control molecules and/or any suitable molecules.
- determining interaction parameters associated with controls and/or associated with compounds can apply one or more of: extracting features, performing pattern recognition on data, fusing data from multiple sources, combination of values (e.g., averaging values, etc.), compression, conversion (e.g., digital-to-analog conversion, analog-to-digital conversion), performing statistical estimation on data (e.g.
- determining interaction parameters associated with controls and/or associated with compounds can apply artificial intelligence approaches (e.g., machine learning approaches, etc.) including any one or more of: supervised learning (e.g., using logistic regression, using back propagation neural networks, using random forests, decision trees, etc.), unsupervised learning (e.g., using an Apriori algorithm, using K-means clustering), semi-supervised learning, a deep learning algorithm (e.g., neural networks, a restricted Boltzmann machine, a deep belief network method, a convolutional neural network method, a recurrent neural network method, stacked auto-encoder method, etc.), reinforcement learning (e.g., using a Q-learning algorithm, using temporal difference learning), a regression algorithm (e.g., ordinary least squares, logistic regression, stepwise regression,
- supervised learning e.g., using logistic regression, using back propagation neural networks, using random forests, decision trees, etc.
- unsupervised learning e.g., using an Apriori algorithm, using K-me
- Control molecules preferably include one or more of choline, DMB, and/or L-carnitine, but can additionally or alternatively include any suitable substrates that bind to any suitable targets (e.g., substrates binding to CutC enzymes and/or CntA enzymes; etc.), any suitable molecules associated with any suitable targets and/or conditions, and/or any suitable molecules.
- suitable targets e.g., substrates binding to CutC enzymes and/or CntA enzymes; etc.
- determining interaction parameters associated with one or more controls S 140 can be performed in any suitable manner.
- embodiments of the method 100 can include determining a set of compound binding parameters (and/or other suitable interaction parameters; etc.) to the one or more targets based on a set of experiments with the one or more models and a library of compounds (e.g., with the potential to affect the one or more targets, such as the potential to inhibit CutC enzymes and/or CntA enzymes; etc.) S 150 , which can function to determine characteristics describing interactions between one or more compounds (e.g., potential compounds, etc.) and one or more targets.
- a set of compound binding parameters and/or other suitable interaction parameters; etc.
- Compound binding parameters are preferably determined for a library of compounds including any suitable number of compounds. Determining the library of compounds can be based on any suitable parameters (e.g., similarity to structures, number of atoms, and/or other suitable characteristics of control molecules, molecules naturally associated with one or more targets, and/or other suitable molecules; databases of molecules; number of compounds; type of targets; type of conditions; molecules that do not infringe Lipinski rules of druggability; etc.).
- suitable parameters e.g., similarity to structures, number of atoms, and/or other suitable characteristics of control molecules, molecules naturally associated with one or more targets, and/or other suitable molecules; databases of molecules; number of compounds; type of targets; type of conditions; molecules that do not infringe Lipinski rules of druggability; etc.
- determining a library of compounds can include selecting only compounds with a number of atoms similar to (e.g., within a threshold of) a number of atoms of choline, DMB, and/or L-carnitine (e.g., within a limit of 28 atoms; etc.).
- the library of compounds can include around 24,000 molecules, but can include any suitable number of molecules.
- Determining compound binding parameters and/or other interaction parameters is preferably based on a set of experiments (e.g., types of experiments described in relation to S 140 ), such as based on docking simulations using the one or more generated models (e.g., models for CutC and CntA enzymes for Firmicutes and Proteobacteria) and simulating binding by the compounds in relation to the models.
- a set of experiments e.g., types of experiments described in relation to S 140
- the one or more generated models e.g., models for CutC and CntA enzymes for Firmicutes and Proteobacteria
- Determining compound binding parameters can be used to determine the binding parameters included in Tables 1-8.
- Determining compound binding parameters can be performed in a same, similar, analogous, or different manner than determining control binding parameters.
- determining interaction parameters associated with one or more compounds S 150 can be performed in any suitable manner.
- embodiments of the method 100 can include identifying at least one compound (e.g., from the library of compounds; etc.), based on the one or more control binding parameters and the set of compound binding parameters S 160 , which can function to identify at least one compound for treating a patient with a condition associated with at least one of trimethylamine (TMA), trimethylamine N-oxide (TMAO), and derivatives thereof, and/or for treating a patient with any suitable conditions.
- TMA trimethylamine
- TMAO trimethylamine N-oxide
- Identifying compounds is preferably based on a comparison between one or more control binding parameters and the set of compound binding parameters (e.g., filtering a library of compounds for compounds with corresponding compound binding parameters greater than one or more of the control binding parameters, etc.). Additionally or alternatively, identifying compounds can be based on control binding parameters and compound binding parameters in any suitable manner, and/or can be based on an y suitable interaction parameters associated with the one or more control molecules and/or any suitable interaction parameters associated with the compounds.
- identifying compounds can include selecting, from a library of compounds (e.g., selected based on atom number similarity to choline and/or DMB, within a limit of 28 atoms; etc.), compounds with equal or greater binding affinity (e.g., as indicated by binding energy value; etc.) for CutC enzymes than choline.
- a library of compounds e.g., selected based on atom number similarity to choline and/or DMB, within a limit of 28 atoms; etc.
- binding affinity e.g., as indicated by binding energy value; etc.
- compounds e.g., with equal or greater binding affinity for CutC enzymes than choline; etc.
- can be filtered e.g., further filtered; etc.
- non-infringement e.g., non-violation; etc.
- Lipinski rules of druggability such as including molecular weight ⁇ 500 Daltons, number of H-bonds donor ⁇ 5, number of H-bonds acceptor ⁇ 10, number of N and O atoms ⁇ 15, range of partition coefficient log P between ⁇ 2 and 5, number of rotatable bonds ⁇ 10, number of ring number ⁇ 10.
- compounds e.g., equal or greater binding affinity for CutC enzymes than choline, and/or not violating Lipinski rules of druggability; etc.
- identifying compounds can include selecting, from a library of compounds (e.g., selected based on atom number similarity to choline, DMB, and/or L-carnitine, within a limit of 28 atoms; etc.), compounds with equal or greater binding affinity (e.g., as indicated by binding energy value; etc.) for CntA enzymes than L-carnitine.
- a library of compounds e.g., selected based on atom number similarity to choline, DMB, and/or L-carnitine, within a limit of 28 atoms; etc.
- binding affinity e.g., as indicated by binding energy value; etc.
- compounds e.g., with equal or greater binding affinity for CntA enzymes than L-carnitine; etc.
- can be filtered e.g., further filtered; etc.
- non-infringement e.g., non-violation; etc.
- Lipinski rules of druggability such as including molecular weight ⁇ 500 Daltons, number of H-bonds donor ⁇ 5, number of H-bonds acceptor ⁇ 10, number of N and O atoms ⁇ 15, range of partition coefficient log P between ⁇ 2 and 5, number of rotatable bonds ⁇ 10, number of ring number ⁇ 10.
- compounds e.g., equal or greater binding affinity for CntA enzymes than L-carnitine, and/or not violating Lipinski rules of druggability; etc.
- can be filtered e.g., further filtered; etc. out if the molecule includes any atoms different from C—H—O—N atoms.
- Identified compounds are preferably usable for treating patients with one or more conditions associated with the at least one of TMA, TMAO, and derivatives thereof, and/or for treating patients with any suitable conditions.
- identified compounds can be used in administering a therapeutically effective amount of the one or more compounds (e.g., in relation to Silo). Additionally or alternatively, identified compounds can be used for any suitable purpose.
- identifying compounds S 160 can be performed in any suitable manner.
- embodiments of the method 100 can include validating one or more compounds S 170 , which can function to experimentally validate and/or otherwise test one or more compounds.
- Any suitable compounds described herein can be validated (e.g., experimentally tested, etc.).
- Compounds can preferably be validated in relation to effect on one or more targets (e.g., CutC enzymes, CntA enzymes, etc.).
- targets e.g., CutC enzymes, CntA enzymes, etc.
- compounds can be validated in relation to ability of the compounds to inhibit conversion of choline (e.g., in the context of CutC enzymes, etc.) or L-carnitine (e.g., in the context of CntA enzymes) into trimethylamine (TMA) by gut microbiota.
- TMA trimethylamine
- TMAO trimethylamine N-oxide
- any suitable molecules described herein can be validated for any suitable purpose, such as by applying any one or more techniques described herein.
- experiments are carried out using cultures of bacterial strains that produce either CutC/CutD or CntA/CntB enzymes.
- cultures of Acinetobacter baumranii Proteobacteria, aerobic, CntA/CntB producer
- Proteus minrabilis Proteobacteria, anaerobic, CutC/CutD producer
- Sporosarcina newyorkensis DSM 235.40 (Firmicutes, CntA/CntB producer, aerobic) and/or Streptococcus dysgaiactae DSM123147 (Firmicutes, CutC/CutD producer, anaerobic) can be used.
- an experimental setup includes evaluation of the gradual consumption of either choline and/or L-carnitine, and/or the progressive production of TMA.
- L-carnitine and choline can quantified in each sample using standard quantification kits (e.g., MAK056 and MAK063, Sigma-Aldrich).
- TMA quantification can be carried out using cation exchange ion chromatography equipped with a separation column and a conductivity detector.
- TMA lyase activity can be quantified in vitro by incubating, for example: a cell lysate (typically ⁇ 3 mg protein), an isolated enzyme (typically ⁇ 30 ⁇ g protein), cultured live microbe (OD 600nm ⁇ 1.0), and/or over cecal lysate with a d9-labeled synthetic substrate (100 ⁇ M, choline or L-carnitine, during 10-16 h).
- TMA lyase activity can be monitored by quantifying d9-TMA production by LC/MS/MS analysis.
- TMA production can be detected from supernatants of the culture cells, using cation-exchange ion chromatography.
- any suitable quantification techniques can be applied, such as for validating one or more compounds.
- a dose response curve of the control compound DMB (e.g., after incubation by 10-16h) can be obtained on each culture to verify decrease of TMA production; and one or more dose response curves can be obtained for each compound (e.g., described in Tables 1-8; described herein; etc.), such as by incubating the compounds (e.g., 10-16h) into the corresponding intact cell cultures (e.g., where cell lysates and/or isolated enzymes can additionally or alternatively be used), using as substrates L-carnitine and/or choline at different concentrations (e.g., as an example, 20, 40, 60, 80, 100 ⁇ M), and then measuring the TMA production at each point.
- a typical concentration used for the compounds to inhibit production of TMA in an intact cell culture is at the scale of ⁇ 1 mM.
- experiments applying techniques described above can be performed in Escherichia coli lysates expressing either CtutC/CutD or CntA/CntB enzymes from Proteobacteria and/or Firmicutes bacteria species mentioned above.
- TMA lyase (CutC/CntA) inhibitory ability, or IC50 under the presence of claimed compounds can be assessed over isolated enzymes lysates (e.g., at the scale of ⁇ 30 ug), where enzymes can be expressed in a model organism (e.g., E. coli Top10) and later purified.
- one or more dose response curves can be generated by testing compounds over the isolated enzymes lysates in increasing concentrations in the range between 1 and 1000 ⁇ M.
- IC50 values of compounds are in the range of ⁇ 10 ⁇ M.
- any of the variants described herein e.g., embodiments, variations, examples, specific examples, figures, etc.
- any portion of the variants described herein can be additionally or alternatively combined, aggregated, excluded, used, performed serially, performed in parallel, and/or otherwise applied.
- Portions of embodiments of the method 100 and/or system 200 can be embodied and/or implemented at least in part as a machine configured to receive a computer-readable medium storing computer-readable instructions.
- the instructions can be executed by computer-executable components that can be integrated with the system 200 .
- the computer-readable medium can be stored on any suitable computer-readable media such as RAMs, ROMs, flash memory, EEPROMs, optical devices (CD or DVD), hard drives, floppy drives, or any suitable device.
- the computer-executable component can be a general or application specific processor, but any suitable dedicated hardware or hardware/firmware combination device can alternatively or additionally execute the instructions.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Evolutionary Biology (AREA)
- Theoretical Computer Science (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- This application claims the benefit of U.S. Provisional Application Ser. No. 62/545,056 filed 14 Aug. 2017, which is herein incorporated in its entirety by this reference. This application additionally claims the benefit of U.S. Provisional Application Ser. No. 62/545,065 filed 14 Aug. 2017, which is herein incorporated in its entirety by this reference.
- The disclosure generally relates to microbiology.
- The concept of drugging microbial targets (e.g., drugging the microbiome, etc.) can include one or more therapeutic approaches avoiding targeting human cells directly, and/or avoiding side effects derived from gene therapy; and instead targeting receptors and enzymes belonging to microbiota. Such approaches can avoid knocking-down the action of human enzymes by gene therapy methods, where such enzymes are not only possibly involved in the production of undesirable metabolites, but can also exert beneficial effects on the organism.
- Choline is a crucial nutrient for humans and other organisms, contributing to different roles in biological pathways as cell membrane function, methyl transfer events, and neurotransmission. In addition to choline, the trimethylamine (TMA) metabolite is an important source of nitrogen, and it is also a carbon source for bacteria that convert TMA in greenhouse gas methane in marine environments. These small molecules are connected through the choline trimethylamine-lyase (CutC) enzyme, which is a glycine radical enzyme that performs the cleavage of the C—N bond in choline to produce trimethylamine (TMA) and acetaldehyde as follows: Choline=trimethylamine+acetaldehyde.
- Gut bacteria and/or other suitable microorganisms from any suitable body sites can play a critical role in triggering and progression of some diseases. Human gut microbiota has been described as producing TMA from choline; a process that is exclusively found in microbes. Choline degradation is the major source of TMA formation within the intestines. Specifically, gut bacteria diet can have an incidence on the production of TMA and its derivative product trimethylamine-N-oxide (TMAO). For example, TMA metabolite, which is often obtained from meat, egg (e.g., egg yolk, etc.), fat-rich food, and/or dairy products is absorbed and converted to TMAO in the liver by the action of the human Flavin-containing monooxygenase 3 (FMO3) enzyme.
- Patients having high TMA levels display higher probabilities of suffering a heart attack. These aspects have become particularly relevant when recent studies have discarded that saturated fats and cholesterol are correlated with an increased risk of heart diseases and atherosclerosis.
- TMAO is a metabolite that has been associated with a high risk of cardiovascular and renal diseases, and additionally, high levels of TMAO produced from choline can trigger atherosclerosis in mice. Two main TMA synthesis pathways have been described in bacteria, one using choline as a substrate (CutC/CutD complex) and the other one using L-carnitine (the two-component Rieske-type oxygenase/reductase CntA/B). Genes encoding CntA/B have been described in several taxa belonging to Betaproteobacteria as well as from a few Firmicutes.
- Regarding one of the main TMA synthesis pathways described, the pathway uses choline as a substrate (CutC/CutD complex). TMA is absorbed and is converted in the liver to TMAO by the action of the FMO3 enzyme. FMO3 participates in host-gut microbiota metabolic interactions. Some strategies have proposed to knock-down the expression of FMO3 enzymes using antisense oligonucleotides that inhibit transcription of its mRNA. While directly reducing choline or L-carnitine ingestion may produce undesired effects, since these molecules can be beneficial in lower quantities, inhibiting FMO3 enzyme to reduce TMAO levels can also undesirable, because accumulation of TMA produces (e.g., through suppression of FMO3 enzymes) conditions or side effects such as hepatic inflammation and/or trimethylaminuria (e.g., fish odor syndrome; fish malodor disorder; etc.).
-
FIG. 1 includes a flowchart representation of variations of an embodiment of a method; -
FIG. 2 includes a flowchart representation of variations of an embodiment of a method; -
FIG. 3 includes a graphical representation of variations of an embodiment of a method. - The following description of the embodiments is not intended to limit the embodiments, but rather to enable any person skilled in the art to make and use.
- As shown in
FIGS. 1-3 , embodiments of a method 100 (e.g., for treating a patient with a condition associated with at least one of TMA, TMAO, and/or derivatives thereof; etc.) can include administering, to a patient with one or more conditions (e.g., one or more conditions associated with the at least one of TMA, TMAO, and/or derivatives thereof; etc.), a therapeutically effective amount of a compound (e.g., drug; etc.) for affecting (e.g., inhibiting; etc.) one or more targets Silo (e.g., CutC enzymes; Rieske-type oxygenase (CntA) enzymes; other enzymes; proteins; other biological targets; non-biological targets; enzymes associated with at least one of TMA, TMAO, and/or derivatives thereof; etc.) associated with microorganisms from at least one taxon from a set of microorganism taxa (e.g., from at least one of Firmicutes (phylum) and Proteobacteria (phylum); etc.). - In an example, a method 100 (e.g., for treating a patient with one or more conditions associated with at least one of TMA, TMAO, and/or derivatives thereof; etc.) can include administering, to the patient with the one or more conditions, a therapeutically effective amount of a compound for inhibiting CutC enzymes of microorganisms from at least one of Firmicutes (phylum) and Proteobacteria (phylum), where the compound (e.g., including one or more constituents, such as any suitable combination of constituents; etc.) includes at least one of: 2-Ethyl-1-butanol; (2R)-3,3-Dimethyl-1,2-butanediol; (2S)-3,3-Dimethyl-1,2-butanediol; (2S)-4-Methyl-2-pentanol; (2S)-3-Methyl-2-butanol; (2R)-4-Methyl-2-pentanol; (2R)-3-Methyl-2-butanol; (2S)-2-Pentanol; (2S)-2-Methyl-1,4-butanediol; 2-Methyl-2,4-butanediol; Trimethylolpropane; 3-(4-Methoxyphenyl)propanal; 1-(3-Pyridinyl)-2-propanamine; 2-[(2R)-2-Butanyl]phenol; 4-Propylbenzoic acid; (2S)-1-(Benzyloxy)-2-propanol; Methyl 3-(4-hydroxyphenyl)propanoate; α-Methylphenylalanine; 2,2-Dimethyl-1-phenyl-1-propanol; Methyl (2R)-hydroxy(phenyl)acetate; (2S)-2-Phenylpyrrolidinium; 4-Methyl-3-phenyl-1,2-oxazol-5-amine; 4,4′-Biphenyldiamine; 4′-Methyl-2-biphenylcarbonitrile; 4-Biphenylol; 2-[3-(4-Methylphenyl)-1,2-oxazol-5-yl] ethanol; 4-Biphenylcarboxamide; 4-Ethynylbiphenyl; 5-(4-Methylphenyl)-1H-1,2,4-triazol-3-amine; 5-(4-Methylphenyl)-1H-pyrazol-3-amine; 4-Hydroxycatechol; 3-Phenyl-1H-pyrazole-5-carbohydrazide; 4-Methyl-1,3-benzenediol; N-(2-Hydroxyethyl)-1,3-propanediaminium; 3-Methoxy-3-methylbutanol; 4-Pyridinylmethanaminium; N-Methyl-3-pyridinamine; 2-Methoxypyridine; 5-Methyl-3-pyridinamine; 1-(4-Methyl-3-pyridinyl)methanamine; Mesitylene; (E)-Benzaldoxime’ (3R)-2,2,4-Trimethyl-1,3-pentanediol; (1R,4R)-2-Azabicyclo[2.2.1]hept-2-ylacetic acid; 3-ACETYLPHENOL; 3-Hydroxybenzoicacid; 1H-Indol-7-ylmethanol; 3-Vinylaniline; (3s,5s,7s)-1-Isocyanatoadamantane; (1R,2S,5R)-2-Hydroxy-2,6,6-trimethylbicyclo[3.1.1]heptan-3-one; (−)-β-Pinene; 2H-Isoindole-1,3-diamine; (3s,5s,7s)-1-Adamantanol; (3-Aminobicyclo[2.2.1]hept-2-yl)methanol; 3-(Hydrazinomethyl)phenol; (1S,2R)-2-Carbamoylcyclohexanaminium; (1S,4R)-1,3,3-Trimethylbicyclo[2.2.1]heptan-2-one; (1R,4S)-1,3,3-Trimethylbicyclo[2.2.1]heptan-2-one; Methyl 4-methyl-4-piperidinecarboxylate; Methyl heptanoate; 3-Methylpyridazine; 4,5-Dimethyl-1,2-oxazol-3-amine; 2-(2-Hydroxyethoxy)phenol; 2-Hydroxy-N-(3-pyridinylmethyl)ethanaminium; 3-Phenyl-1-propanol; (2R)-6-Methyl-2-heptanol; 2-Phenoxyacetohydrazide; N-Hydroxyoctanamid; Cyclobutanecarbohydrazide; Phenylhydrazine; (1S,4R)-2-Azabicyclo[2.2.1]hept-5-en-3-one; salicylamide; Adamantane; 3-Azabicyclo[3.3.1]nonane; N-Hydroxy-2-methylbenzenecarboximidamide; (−)-camphene; (1S,2S,4S)-Bicyclo[2.2.1]hept-5-en-2-ylmethanol; Dicyclopentadiene; (8-anti)-3-Azabicyclo[3.2.1]octan-8-ol; (1R,2S,6R,7S)-Tricyclo[5.2.1.02,6]deca-3,8-diene; any suitable compounds including any suitable combination of any suitable compounds and/or structures (e.g., of one or more structures; etc.) included in Tables 1-4; and/or any pharmaceutically acceptable forms thereof; and/or salts of thereof.
- In an example, a method 100 (e.g., for treating a patient with one or more conditions associated with at least one of TMA, TMAO, and/or derivatives thereof; etc.) can include administering, to the patient with the one or more conditions, a therapeutically effective amount of a compound for inhibiting CntA enzymes of microorganisms from at least one of Firmicutes (phylum) and Proteobacteria (phylum), where the compound (e.g., including one or more constituents, such as any suitable combination of constituents; etc.) includes at least one of: N-Methylglutamic acid; 4-(1-Pyrrolidinyl)butanoic acid; 4-Methyl-4-piperidinecarboxylic acid; Isonipecotic acid; N-propylbenzene; N-Ethyl-2-pyridinamine; (4R)-4-Amino-1-propyl-2-pyrrolidinone; 2,5-Diaminotoluene; Ethyl phenyl ether; Phenylcyanate; 1-(2-Cyclopenten-1-yl)acetone; 2-Amino-3-methylpyridinium; E-pyridine-3-aldoxime; N-Cyclohexylformamide; 2-Methyl-2-hexenoic acid; 4-Heptanaminium; 3,4-Anhydro-3-carboxy-2-deoxy-L-threo-pentaric acid; 2,2′-[(2-Hydroxyethyl)imino]diacetic acid; 1H-Tetrazol-5-ylacetic acid; Diacetylacetone; (2S)-2-Acetoxypropanoic acid; 4,4′-Biphthalic anhydride; Bis(1H-benzotriazol-1-yl)methanone; 2-Anthraquinonesulfonic acid; 3-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)benzonitrile; 2-phenylquinazolin-4-ol; 4-Amino-2-(1,3-benzothiazol-2-yl)phenol; 4-Phenyl-1(2H)-phthalazinone; 5-(1,3-Benzodioxol-5-yl)-2-methyl-3-furoic acid; (5R)-5-(2-Naphthyl)dihydro-2(3H)-furanone; 3-[5-(3-Methylphenyl)-1,3,4-oxadiazol-2-yl]propanoic acid; 9-ETHYNYLPHENANTHRENE; PHA-767491; 3-Amino-2-methylphenol; 5-(4-Methylphenyl)-2-furoic acid; 8-Methyl-4H-thieno[3,2-c]chromene-2-carboxylic acid; resorcinol monobenzoate; 3-Methoxy-4-biphenylcarbaldehyde; (7-Amino-4-methyl-2-oxo-2H-chromen-3-yl)acetic acid; 2,3-Dihydro-1H-inden-5-yl(oxo)acetic acid; 3-(2-Pyridyl)aniline; 4-(3-Methyl-1H-1,2,4-triazol-5-yl)aniline; Benzidine; (DL)-3-O-Methyldopa; Methyl (2E)-3-(2-amino-5-methyl-3-pyridinyl)acrylate; (5-Methylfuro[2,3-b]pyridin-2-yl)methanol; (2R)-2,3-Dihydro-1,4-benzodioxin-2-ylmethanaminium; R-phenylethyl propionate; i-propyl benzoate; 4-Acetotoluide; (1S)-1-(2,5-Dimethylphenyl)ethanaminium; (1R)-2-Methyl-2,5-cyclohexadiene-1-carboxylic acid; (2,2-Dimethoxyethyl)benzene; any suitable compounds including any suitable combination of any suitable compounds and/or structures (e.g., of one or more structures; etc.) included in Tables 5-8; and pharmaceutically acceptable forms thereof; and/or salts of thereof.
- Additionally or alternatively, as shown in
FIGS. 2-3 , embodiments of the method 100 (e.g., for identifying at least one compound for treating a patient with a condition associated with at least one of TMA, TMAO, and/or derivatives thereof; etc.) can include determining one or more representative sequences (e.g., nucleic acid sequence; amino acid sequence; etc.) of one or more targets (e.g., CutC enzymes; CntA enzymes; other enzymes; proteins; other biological targets; non-biological targets; enzymes associated with at least one of TMA, TMAO, and/or derivatives thereof; etc.) S120, such as where the one or more representative sequences are representative of one or more sets of sequences of the one or more targets for at least one taxon of a set of microorganism taxa (e.g., a representative sequence representative of a plurality of sequences of the target from a plurality of different taxa, such as from Firmicutes (phylum) and Proteobacteria (phylum); etc.); generating one or more models (e.g., protein structure models; etc.) of the one or more targets based on the one or more representative sequences of the one or more targets S130; determining one or more control binding parameters (and/or other suitable interaction parameters; etc.) to the one or more targets based on one or more experiments (e.g., control docking simulations; other computational simulations; other experiments; etc.) with the one or more models and one or more control molecules (e.g., 3,3-dimethyl-1-butanol; L-carnitine; etc.) S140; determining a set of compound binding parameters (and/or other suitable interaction parameters; etc.) to the one or more targets based on a set of experiments (e.g., control docking simulations; other computational simulations; other experiments; etc.) with the one or more models and a library of compounds (e.g., with the potential to affect the one or more targets, such as the potential to inhibit CutC enzymes and/or CntA enzymes; etc.) S150; identifying at least one compound (e.g., from the library of compounds; etc.) for treating the patient with the condition associated with the at least one of TMA, TMAO, and derivatives thereof, based on a comparison between one or more control binding parameters (and/or other suitable interaction parameters associated with the one or more control molecules; etc.) and the set of compound binding parameters (and/or other suitable interaction parameters associated with the compounds; etc.) S160; and/or validating one or more compounds S170. - Embodiments of the
method 100 and/orsystem 200 can function to diagnose and/or treat one or more patients with one or more conditions associated with at least one of TMA, TMAO, and/or derivatives thereof, such as by using and/or administering (and/or other suitable provision and/or promotion) of one or more compounds affecting one or more targets (e.g., inhibiting CutC enzymes; inhibiting CntA enzymes; etc.) associated with the one or more conditions (e.g., correlated with, causative; etc.) and/or associated with microorganisms from at least one taxon from a set of taxa (e.g., from at least one of Firmicutes (phylum) and Proteobacteria (phylum); etc.). Additionally or alternatively, embodiments of themethod 100 and/orsystem 200 can function to identify one or more compounds that can be administered for treating one or more patients with one or more conditions (e.g., associated with at least one of TMA, TMAO, and/or derivatives thereof; etc.). - In an example, the
method 100 can screen libraries of compounds (e.g., including any suitable number of compounds; etc.), based on molecular docking simulations, for identifying compounds (e.g., drugs; etc.) that can bind the active site of one or more targets (e.g., CutC enzymes; CntA enzymes; etc.) from microorganisms (e.g., from Firmicutes (phylum) and/or Proteobacteria (phylum); etc.) and associated with TMA, TMAO, and/or derivatives thereof, such as for identifying compounds with therapeutic effects (e.g., by inhibiting production of TMA; TMAO; derivatives thereof; etc.) on conditions associated with TMA, TMAO, and/or derivatives thereof. In an example, themethod 100 can overcome side effects and/or complications associated with inhibiting FMO3 enzyme, such as by selectively inhibiting pathways producing TMA, such as CutC/CutD and/or CntA/CntB. - Conditions (e.g., treatable by the one or more compounds; etc.) preferably include conditions associated with characterizations and/or therapies for one or more microorganism-related conditions associated with at least one of TMA, TMAO, and/or derivatives thereof (e.g., conditions triggerable, caused by, correlated with, and/or otherwise associated with one or more of TMA, TMAO, and/or derivatives thereof, such as a high amounts of TMA, TMAO, and/or derivatives thereof; etc.). Conditions associated with at least one of TMA, TMAO, and/or derivatives thereof can include any one or more of: cardiovascular conditions (e.g., atherosclerosis; severe heart failure; coronary heart disease; inflammatory heart disease; valvular heart disease; obesity; stroke; thrombosis, platelet responsiveness, etc.); renal conditions (e.g., renal failure; chronic kidney disease; polycystic kidney disease; glomerulonephritis; IgA nephropathy; nephritis; nephrotic syndrome; lupus; kidney cancer; rare kidney diseases; etc.); metabolic-related conditions (e.g., trimethylaminuria (TMAU); etc.); nutrition-related conditions (e.g., weight-related conditions such as weight-loss conditions; blood sugar-related conditions such as high blood sugar-related conditions; allergy-related conditions such as allergies and/or intolerance associated with wheat, gluten, dairy, soy, peanut, shellfish, tree nut, egg; etc.).
- Additionally or alternatively, conditions can include any one or more of: gastrointestinal-related conditions (e.g., irritable bowel syndrome, inflammatory bowel disease, ulcerative colitis, celiac disease, Crohn's disease, bloating, hemorrhoidal disease, constipation, reflux, bloody stool, diarrhea, etc.); skin-related conditions (e.g., acne, dermatomyositis, eczema, rosacea, dry skin, psoriasis, dandruff, photosensitivity, rough skin, itching, flaking, scaling, peeling, fine lines or cracks, gray skin in individuals with dark skin, redness, deep cracks such as cracks that can bleed and lead to infections, itching and scaling of the skin in the scalp, oily skin such as irritated oily skin, skin sensitivity to products such as hair care products, imbalance in scalp microbiome, etc.); locomotor-related conditions (e.g., gout, rheumatoid arthritis, osteoarthritis, reactive arthritis, multiple sclerosis, Parkinson's disease, etc.); cancer-related conditions (e.g., lymphoma; leukemia; blastoma; germ cell tumor; carcinoma; sarcoma; breast cancer; prostate cancer; basal cell cancer; skin cancer; colon cancer; lung cancer; cancer conditions associated with any suitable physiological region; etc.); anemia conditions; neurological-related conditions (e.g., ADHD, ADD, anxiety, Asperger's syndrome, autism, chronic fatigue syndrome, depression, etc.); autoimmune-related conditions (e.g., Sprue, AIDS, Sjogren's, Lupus, etc.); endocrine-related conditions (e.g., obesity, Graves' disease, Hashimoto's thyroiditis, metabolic disease, Type I diabetes, Type II diabetes, etc.); Lyme disease conditions; communication-related conditions; sleep-related conditions; pain-related conditions; genetic-related conditions; chronic disease; and/or any other suitable type of conditions. Additionally or alternatively, conditions can include one or more human behavior conditions which can include any one or more of: caffeine consumption, alcohol consumption, other food item consumption, dietary supplement consumption, probiotic-related behaviors (e.g., consumption, avoidance, etc.), other dietary behaviors, habituary behaviors (e.g., smoking; exercise conditions such as low, moderate, and/or extreme exercise conditions; etc.), menopause, other biological processes, social behavior, other behaviors, and/or any other suitable human behavior conditions.
- Conditions can include one or more of: diseases, symptoms, causes (e.g., triggers, etc.), disorders, associated risk (e.g., propensity scores, etc.), associated severity, behaviors (e.g., caffeine consumption, habits, diets, etc.), and/or any other suitable aspects associated with conditions. Conditions can be associated with any suitable phenotypes (e.g., phenotypes measurable for a human, animal, plant, fungi body, etc.).
- In examples, the condition (e.g., one or more conditions; etc.) can include at least one of: a cardiovascular condition (e.g., atherosclerosis; etc.), a renal condition (e.g., renal failure; etc.), a metabolic-related condition (e.g., trimethylaminuria; etc.), and/or a nutrition-related condition (e.g., a weight-related condition; a high blood sugar-related condition; etc.); where the condition can be associated with at least one of TMA, TMAO, and/or derivatives thereof; and where administering to one or more patients can include administering, to the one or more patients with the one or more conditions (e.g., etc.;), a therapeutically effective amount of one or more compounds (e.g., any suitable compounds in and/or including any suitable combination of compounds from Tables 1-8; etc.) for inhibiting one or more enzymes (e.g., CutC enzymes; CntA enzymes; enzymes associated with the at least one of TMA, TMAO, and/or derivatives thereof; etc.) of microorganisms from at least one of Firmicutes (phylum) and/or Proteobacteria (phylum).
- Additionally or alternatively, data described herein (e.g., binding parameters; interaction parameters; identified compounds; outputs from models and/or experiments; etc.) can be associated with any suitable temporal indicators (e.g., seconds, minutes, hours, days, weeks, time periods, time points, timestamps, etc.) including one or more: temporal indicators indicating when the data was collected, determined, transmitted, received, and/or otherwise processed; temporal indicators providing context to content described by the data; changes in temporal indicators (e.g., data over time; change in data; data patterns; data trends; data extrapolation and/or other prediction; etc.); and/or any other suitable indicators related to time.
- Additionally or alternatively, parameters, metrics, inputs, outputs, and/or other suitable data can be associated with value types including any one or more of: scores (e.g., binding parameters; interaction parameters; etc.), binary values (e.g., presence of a target within a microorganism taxon; etc.), classifications (e.g., taxon classifications; etc.), confidence levels, identifiers (e.g., compound identifiers; etc.), values along a spectrum, and/or any other suitable types of values. Any suitable types of data described herein can be used as inputs (e.g., for different models described herein; for portions of embodiments the
method 100; etc.), generated as outputs (e.g., of models), and/or manipulated in any suitable manner for any suitable components associated with embodiments of themethod 100 and/orsystem 200. - One or more instances and/or portions of embodiments of the
method 100 and/or processes described herein can be performed asynchronously (e.g., sequentially), concurrently (e.g., in parallel; concurrently on different threads for parallel computing to improve system processing ability for screening and/or otherwise determining compounds; etc.), in temporal relation to a trigger event (e.g., performance of a portion of the method 100), and/or in any other suitable order at any suitable time and frequency by and/or using one or more instances of embodiments of thesystem 200, components, and/or entities described herein. - Embodiments of the
system 200 can include any one or more of: compounds and/or pharmaceutically acceptable forms thereof, and/or salts (e.g., pharmaceutically acceptable salts; etc.) thereof; computing systems (e.g., for identifying one or more compounds; etc.); sample handling networks; sequencing systems; and/or any other suitable components. Thesystem 200 and/or portions of thesystem 200 can entirely or partially be executed by, hosted on, communicate with, and/or otherwise include: a remote computing system (e.g., a server, at least one networked computing system, stateless, stateful; etc.), a local computing system, a user device (e.g., mobile phone device, other mobile device, personal computing device, tablet, wearable, head-mounted wearable computing device, wrist-mounted wearable computing device, etc.), a care provider device, databases, application programming interfaces (APIs) (e.g., for accessing data described herein, etc.) and/or any suitable components. Communication by and/or between any components of thesystem 200 can include wireless communication (e.g., WiFi, Bluetooth, radiofrequency, Zigbee, Z-wave, etc.), wired communication, and/or any other suitable types of communication. The components of thesystem 200 can be physically and/or logically integrated in any manner (e.g., with any suitable distributions of functionality across the components, such as in relation to portions of embodiments of themethod 100; etc.). - Portions of embodiments of the
method 100 and/orsystem 200 can be performed by any one or more of: first parties; third parties; car providers (e.g., doctors; nurses; etc.); lab technicians; users; compound providers; and/or any suitable entities. - However, embodiments of the
method 100 and/orsystem 200 can be configured in any suitable manner. - Embodiments of the
method 100 can include administering (and/or other suitable provision of; promotion of; etc.) administering one or more compounds (e.g., a therapeutically effective amount of the one or more compounds; etc.) to one or more patients with one or more conditions Silo (e.g., one or more conditions associated with the at least one of TMA, TMAO, and/or derivatives thereof; etc.), which can function to facilitate treatment of one or more patients. - A therapeutically effective amount of the one or more compounds is preferably administered, but any suitable amounts of the one or more compounds can be administered.
- The compounds (e.g., drugs; molecules; etc.) preferably affect (e.g., inhibiting; etc.) one or more targets (e.g., CutC enzymes; CntA enzymes; etc.) associated with one or more conditions associated at least one of TMA, TMAO, and/or derivatives thereof, such as for inhibiting production of TMA, TMAO, and/or derivatives thereof (e.g., for preventing, treating, and/or reducing the effect of conditions associated with TMA, TMAO, and/or derivatives thereof; etc.). Additionally or alternatively, the compounds can otherwise affect (e.g., activate, upregulate, downregulate, bind; etc.) the one or more targets, and/or the targets can be associated with any suitable conditions. Compounds can include any suitable combination of (e.g., one or more; combinations; individual molecules and/or compounds; etc.), derivative of, pharmaceutically acceptable form of, and/or any suitable form of compounds included in Tables 1-8.
- Compounds can include any suitable pharmaceutically acceptable forms of the compounds, which can include any one or more of: derivatives; pharmaceutically deliverable forms; forms with carriers, agents, supplemental components; salts; and/or any suitable acceptable forms. Compounds can include any suitable salts (e.g., pharmaceutically acceptable salts; etc.) thereof, and/or any suitable forms of the compounds.
- Targets (e.g., targets targeted by the one or more compounds; targets causing, contributing to, with therapeutic effect in relation to, correlated with, and/or otherwise associated with one or more conditions etc.) can include any one or more of: CutC enzymes; CntA enzymes; CutD enzymes; CntB enzymes; other enzymes (e.g., associated with at least one of TMA, TMAO, and/or derivatives thereof; etc.); proteins; target markers (e.g., biomarkers; etc.); targets of interest; known or identified targets; unknown or previously unidentified targets; genetic targets; sequences (e.g., amino acid sequences; nucleic acid sequences; etc.); compounds; peptides; carbohydrates; lipids; nucleic acids; cells (e.g., whole cells, etc.); metabolites; natural products; diagnostic biomarkers; prognostic biomarkers; predictive biomarkers; other molecular biomarkers; biological targets; non-biological targets; other molecules (e.g., associated with at least one of TMA, TMAO, and/or derivatives thereof; etc.); and/or any other suitable targets.
- Targets are preferably associated with microorganisms (e.g., are from the microorganisms; are produced by the microorganisms; have been found in relation to the microorganisms; are present in the microorganisms; are encoded by genetic sequences, amino acid sequences, and/or other suitable sequences of the microorganisms; etc.) from at least one taxon from a set of microorganism taxa (e.g., from at least one of Firmicutes (phylum) and Proteobacteria (phylum); etc.). Additionally or alternatively, targets can be associated with microorganisms from any suitable microorganism taxa (e.g., domain, kingdom, phylum, class, order, family, genus, species; etc.) and/or microorganisms associated with any suitable body site including any one or more of gut, skin, nose, mouth, genitals, and/or any suitable body site. Administering a compound can include any one or more of providing, promoting, and/or otherwise administering a compound.
- Administering one or more compounds can include administering (e.g., a therapeutically effective amount of; etc.) one or more compounds for inhibiting (and/or otherwise affecting) CutC enzymes, such as CutC enzymes of microorganisms from at least one of Firmicutes (phylum), Proteobacteria (phylum), and/or other suitable taxa.
- Compounds for inhibiting (and/or otherwise affecting) CutC enzymes (e.g., associated with microorganisms from at least one of Proteobacteria and Firmicutes; etc.) can include one or more 3,3-dimethyl-1-butanol (DMB) analogues (e.g., binding with equal or higher affinity to CutC enzymes than DMB, such as for CutC enzymes belonging to Proteobacteria and/or Firmicutes; etc.). In examples, DMB can inhibit TMA formation by CutC enzymes (e.g., derived from cultured microbes in a non-lethal way, such as not an antibiotic); can reduce TMAO levels (e.g., in animals with a high choline or carnitine diet; etc.); and/or can bind the active site of CutC enzymes (e.g., with higher affinity than choline, thereby exerting competitive inhibition; etc.). In examples, DMB analogues (and/or compounds generally) can include any one or more compounds included in Table 1.
-
TABLE 1 Examples of Analogues of DMB that can Bind CutC Enzymes of Microorganisms from Proteobacteria and/or Firmicutes. Binding Binding Energy Energy (to CutC (to CutC IUPAC enzyme, enzyme, Structure SMILES code nomenclature Proteobacteria) Firmicutes) CCC(CC)CO 2-Ethyl-1- butanol −4.9 kcal/mol CC(C)(C)[C@](CO)O (2R)-3,3- Dimethyl- 1,2- butanediol −5.5 kcal/mol −5.2 kcal/mol CC(C)(C)[C@@H](CO)O (2S)-3,3- Dimethyl- 1,2- butanediol −5.4 kcal/mol −5.2 kcal/mol C[C@@H](CC(C)C)O (2S)-4- Methyl-2- pentanol −5.2 kcal/mol C[C@@H](C(C)C)O (2S)-3- Methyl-2- butanol −4.8 kcal/mol C[C@H](CC(C)C)O (2R)-4- Methyl-2- pentanol −5.0 kcal/mol C[C@H](C(C)C)O (2R)-3- Methyl-2- butanol −4.8 kcal/mol CCC[C@H](C)O (2S)-2- Pentanol −4.8 kcal/mol C[C@@H](CCO)CO (2S)-2- Methyl-1,4- butanediol −4.9 kcal/mol −5.0 kcal/mol CC(C)(CCO)O 2-Methyl- 2,4- butanediol −4.9 kcal/mol −5.1 kcal/mol CCC(CO)(CO)CO Trimethylol propane −5.2 kcal/mol −5.3 kcal/mol - In an example, administering to the patient with the one or more conditions can include administering, to the patient with the one or more conditions, a therapeutically effective amount of a compound including a 3,3-dimethyl-1-butanol (DMB) analogue including at least one (e.g., any one or more; etc.) of: 2-Ethyl-1-butanol; (2R)-3,3-Dimethyl-1,2-butanediol; (2S)-3,3-Dimethyl-1,2-butanediol; (2S)-4-Methyl-2-pentanol; (2S)-3-Methyl-2-butanol; (2R)-4-Methyl-2-pentanol; (2R)-3-Methyl-2-butanol; (2S)-2-Pentanol; (2S)-2-Methyl-1,4-butanediol; 2-Methyl-2,4-butanediol; Trimethylolpropane; and pharmaceutically acceptable forms thereof (e.g., derivatives thereof; pharmaceutically deliverable forms thereof; etc.); and/or salts (e.g., pharmaceutically acceptable salts; etc.) thereof. However, compounds including a 3,3-dimethyl-1-butanol (DMB) analogue can be configured in any suitable manner, and administering such compounds can be performed in any suitable manner (e.g., for affecting any suitable targets).
- Compounds for inhibiting (and/or otherwise affecting) CutC enzymes can include one or more compounds for inhibiting the CutC enzymes of microorganisms from Firmicutes (phylum), such as where the one or more compounds (and/or compounds generally) can include any one or more compounds included in Table 2 (e.g., where the compounds can include specificity for CutC enzymes from microorganisms from Firmicutes; where the compounds do not bind or bind with lower affinity to CutC enzymes from microorganisms from Proteobacteria; where each compound can be representative of a subset of molecules exerting the same binding energy and such as with similar structure to the compound; where the compounds can include higher affinity, as indicated by the binding energy values, than choline or DMB, to the CutC enzymes; etc.).
-
TABLE 2 Examples of Compounds (e.g., molecules) that can Bind CutC Enzymes of Microorganisms from Firmicutes (e.g., Firmicutes-CoD5P1 CutC Enzyme) Binding Energy (to CutC IUPAC enzyme, Structure SMILES code nomenclature Firmicutes) COc1ccc(cc1)CCC═O 3-(4- Methoxyphenyl)propanal −4.9 kcal/mol C[C@H](Cc1cccnc1)[NH3+] 1-(3-Pyridinyl)-2- propanamine −5.0 kcal/mol CC[C@@H](C)c1ccccc1O 2-[(2R)-2- Butanyl]phenol −5.2 kcal/mol CCCc1ccc(cc1)C(═O)O 4-Propylbenzoic acid −5.3 kcal/mol C[C@@H](COCc1ccccc1)O (2S)-1- (Benzyloxy)-2- propanol −5.4 kcal/mol COC(═O)CCc1ccc(cc1)O Methyl 3-(4- hydroxyphenyl)propanoate −5.5 kcal/mol C[C@@](Cc1ccccc1)(C(═O)O)[NH3+] α- Methylphenyialanine −5.6 kcal/mol CC(C)(C)C(c1ccccc1)O 2,2-Dimethyl-1- phenyl-1- propanol −5.7 kcal/mol COC(═O)[C@@H](c1ccccc1)O Methyl (2R)- hydroxy(phenyl)acetate −5.8 kcal/mol c1ccc(cc1)[C@@H]1CCC[NH2+]1 (2S)-2- Phenylpyrrolidinium −5.9 kcal/mol Cc1c(noc1N)c1ccccc1 4-Methyl-3- phenyl-1,2- oxazol-5-amine −6.0 kcal/mol c1cc(ccc1c1ccc(cc1)N)N 4,4′- Biphenyldiamine −6.1 kcal/mol Cc1ccc(cc1)c1ccccc1C#N 4′-Methyl-2- biphenylcarbonitrile −6.2 kcal/mol c1ccc(cc1)c1ccc(cc1)O 4-Biphenylol −6.3 kcal/mol Cc1ccc(cc1)c1cc(on1)CCO 2-[3-(4- Methylphenyl)-1,2- oxazol-5-yl]ethanol −6.4 kcal/mol c1ccc(cc1)c1ccc(cc1)C(═O)N 4- Biphenylcarboxamide −6.5 kcal/mol C#Cc1ccc(cc1)c1ccccc1 4- Ethynylbiphenyl −6.6 kcal/mol Cc1ccc(cc1)c1nc([nH]n1)N 5-(4-Methylphenyl)- 1H-1,2,4-triazol- 3-amine −6.7 kcal/mol Cc1ccc(cc1)c1cc([nH]n1)N 5-(4- Methylphenyl)- 1H-pyrazol-3-amine −6.8 kcal/mol c1cc(c(cc1O)O)O 4- Hydroxycatechol −6.9 kcal/mol c1ccc(cc1)c1cc(n[nH]1)C(═O)NN 3-Phenyl-1H- pyrazole-5- carbohydrazide −7.0 kcal/mol Cc1ccc(cc1O)O 4- Methyl-1,3- benzenediol −7.1 kcal/mol - In an example, administering to the patient with the one or more conditions can include administering, to the patient with the one or more conditions, a therapeutically effective amount of a compound for inhibiting the CutC enzymes of the microorganisms from Firmicutes (phylum), where the compound includes at least one (e.g., any one or more; etc.) of: 3-(4-Methoxyphenyl)propanal; 1-(3-Pyridinyl)-2-propanamine; 2-[(2R)-2-Butanyl]phenol; 4-Propylbenzoic acid; (2S)-1-(Benzyloxy)-2-propanol; Methyl 3-(4-hydroxyphenyl)propanoate; α-Methylphenylalanine; 2,2-Dimethyl-1-phenyl-1-propanol; Methyl (2R)-hydroxy(phenyl)acetate; (2S)-2-Phenylpyrrolidinium; 4-Methyl-3-phenyl-1,2-oxazol-5-amine; 4,4′-Biphenyldiamine; 4′-Methyl-2-biphenylcarbonitrile; 4-Biphenylol; 2-[3-(4-Methylphenyl)-1,2-oxazol-5-yl]ethanol; 4-Biphenylcarboxamide; 4-Ethynylbiphenyl; 5-(4-Methylphenyl)-1H-1,2,4-triazol-3-amine; 5-(4-Methylphenyl)-1H-pyrazol-3-amine; 4-Hydroxycatechol; 3-Phenyl-1H-pyrazole-5-carbohydrazide; 4-Methyl-1,3-benzenediol; and pharmaceutically acceptable forms thereof (e.g., derivatives thereof; pharmaceutically deliverable forms thereof; etc.); and/or salts (e.g., pharmaceutically acceptable salts; etc.) thereof. However, compounds for inhibiting CutC enzymes of microorganisms from Firmicutes (phylum) can be configured in any suitable manner, and administering such compounds can be performed in any suitable manner (e.g., for affecting any suitable targets).
- Compounds for inhibiting (and/or otherwise affecting) CutC enzymes can include one or more compounds for inhibiting the CutC enzymes of microorganisms from Proteobacteria (phylum), such as where the one or more compounds (and/or compounds generally) can include any one or more compounds included in Table 3 (e.g., where the compounds can include specificity for CutC enzymes from microorganisms from Proteobacteria; where the compounds do not bind or bind with lower affinity to CutC enzymes from microorganisms from Firmicutes; where each compound can be representative of a subset of molecules exerting the same binding energy and such as with similar structure to the compound; where the compounds can include higher affinity, as indicated by the binding energy values, than choline or DMB, to the CutC enzymes; etc.).
-
TABLE 3 Examples of Compounds (e.g., molecules) that can Bind CutC Enzymes of Microorganisms from Proteobacteria (e.g., Proteobacteria-B4EYG1 CutC Enzyme) Binding Energy (to CutC IUPAC enzyme, Structure SMILES code nomenclature Proteobacteria) C(C[NH3+])C[NH2+]CCO N-(2- Hydroxyethyl)- 1,3- propanediaminium −4.8 kcal/mol CC(C)(CCO)OC 3-Methoxy-3- methylbutanol −4.9 kcal/mol c1cnccc1C[NH3+] 4- Pyridinyl- methanaminium −5.0 kcal/mol CNc1cccnc1 N-Methyl-3- pyridinamine −5.1 kcal/mol COc1ccccn1 2- Methoxypyridine −5.2 kcal/mol Cc1cc(cnc1)N 5-Methyl-3- pyridinamine −5.3 kcal/mol Cc1ccncc1C[NH3+] 1-(4-Methyl-3- pyridinyl) methanamine −5.4 kcal/mol Cc1cc(cc(c1)C)C Mesitylene −5.5 kcal/mol c1ccc(cc1)/C═NO (E)-Benzaldoxime −5.6 kcal/mol CC(C)[C@H](C(C)(C)CO)O (3R)-2,2,4- Trimethyl-1,3- pentanediol −5.7 kcal/mol C1C[C@@H]2C[C@H]1C[N@@H+]2CC(═O)O (1R,4R)-2- Azabicyclo[2.2.1] hept-2-ylacetic acid −5.8 kcal/mol CC(═O)c1cccc(c1)O 3- ACETYLPHENOL −5.9 kcal/mol c1cc(cc(c1)O)C(═O)O 3- Hydroxy- benzoicacid −6.0 kcal/mol c1cc2cc[nH]c2c(c1)CO 1H-Indol-7- ylmethanol −6.1 kcal/mol C═Cc1cccc(c1)N 3-Vinylaniline −6.2 kcal/mol C1[C@H]2C[C@H]3C[C@@H]1C[C@@](C2)(C3)N═C═O (3s,5s,7s)-1- Isocyanato- adamantane −6.3 kcal/mol C[C@@]1([C@@H]2C[C@@H](C2(C)C)CC1═O)O (1R,2S,5R)-2- Hydroxy-2,6,6- trimethylbicyclo [3.1.1]heptan-3- one −6.4 kcal/mol CC1([C@H]2CCC(═C[C@@H]1C2)C (−)-β-Pinene −6.5 kcal/mol c1ccc2c(c1)c([nH]c2N)N 2H-Isoindole-1,3- diamine −6.6 kcal/mol C1[C@H]2C[C@H]3C[C@@H]1C[C@@](C2)(C3)O (3s,5s,7s)-1- Adamantanol −6.7 kcal/mol C1C[C@H]2C[C@@H]1[C@H]([C@H]2[NH3+])CO (3- Aminobicyclo [2.2.1]hept-2- yl)methanol −6.8 kcal/mol c1cc(cc(c1)O)CN[NH3+] 3- (Hydrazinomethyl) phenol −6.9 kcal/mol C1CC[C@@H]([C@@H](C1)C(═O)N)[NH3+] (1S,2R)-2- Carbamoylcyclo- hexanaminium −7.0 kcal/mol C[C@]12CC[C@H](C1)C(C2═O)(C)C (1S,4R)-1,3,3- Trimethylbicyclo [2.2.1]heptan-2- one −7.1 kcal/mol C[C@@]12CC[C@@H](C1)C(C2═O)(C)C (1R,4S)-1,3,3- Trimethylbicyclo [2.2.1]heptan-2- one −7.4 kcal/mol - In an example, administering to the patient with the one or more conditions can include administering, to the patient with the one or more conditions, a therapeutically effective amount of a compound for inhibiting the CutC enzymes of the microorganisms from Proteobacteria (phylum), where the compound includes at least one (e.g., any one or more; etc.) of: N-(2-Hydroxyethyl)-1,3-propanediaminium; 3-Methoxy-3-methylbutanol; 4-Pyridinylmethanaminium; N-Methyl-3-pyridinamine; 2-Methoxypyridine; 5-Methyl-3-pyridinamine; 1-(4-Methyl-3-pyridinyl)methanamine; Mesitylene; (E)-Benzaldoxime’ (3R)-2,2,4-Trimethyl-1,3-pentanediol; (1R,4R)-2-Azabicyclo[2.2.1]hept-2-ylacetic acid; 3-ACETYLPHENOL; 3-Hydroxybenzoicacid; 1H-Indol-7-ylmethanol; 3-Vinylaniline; (3s,5s,7s)-1-Isocyanatoadamantane; (1R,2S,5R)-2-Hydroxy-2,6,6-trimethylbicyclo[3.1.1]heptan-3-one; (−)-β-Pinene; 2H-Isoindole-1,3-diamine; (3s,5s,7s)-1-Adamantanol; (3-Aminobicyclo[2.2.1]hept-2-yl)methanol; 3-(Hydrazinomethyl)phenol; (1S,2R)-2-Carbamoylcyclohexanaminium; (1S,4R)-1,3,3-Trimethylbicyclo[2.2.1]heptan-2-one; (1R,4S)-1,3,3-Trimethylbicyclo[2.2.1]heptan-2-one; and pharmaceutically acceptable forms thereof (e.g., derivatives thereof; pharmaceutically deliverable forms thereof; etc.); and/or salts (e.g., pharmaceutically acceptable salts; etc.) thereof. However, compounds for inhibiting CutC enzymes of microorganisms from Proteobacteria (phylum) can be configured in any suitable manner, and administering such compounds can be performed in any suitable manner (e.g., for affecting any suitable targets).
- Compounds for inhibiting (and/or otherwise affecting) CutC enzymes can include one or more compounds for inhibiting the CutC enzymes of microorganisms from Firmicutes (phylum) and Proteobacteria (phylum) (e.g., inhibiting CutC enzymes of first microorganisms from Firmicutes as well as CutC enzymes of second microorganisms from Proteobacteria, etc.), such as where the one or more compounds (and/or compounds generally) can include any one or more compounds included in Table 4 (e.g., compounds binding CutC enzymes associated with Firmicutes, and binding CutC enzymes associated with Proteobacteria; such as where the compounds can inhibit products of TMA by CutC in a set of microorganisms across different taxa, such as across Firmicutes and Proteobacteria; where each compound can be representative of a subset of molecules exerting the same binding energy and such as with similar structure to the compound; where the compounds can include higher affinity, as indicated by the binding energy values, than choline or DMB, to the CutC enzymes; etc.).
-
TABLE 4 Examples of Compounds (e.g., molecules) that can Bind CutC Enzymes of Microorganisms from Proteobacteria and Firmicutes Binding Binding Energy Energy (to CutC (to CutC IUPAC enzyme, enzyme, Structure SMILES code nomenclature Proteobacteria) Firmicutes) CC1(CC[NH2+]CC1)C(═O)OC Methyl 4-methyl- 4- piperidine- carboxylate −4.8 kcal/mol −4.8 kcal/mol CCCCCCC(═O)OC Methyl heptanoate −4.9 kcal/mol −4.9 kcal/mol Cc1cccnn1 3- Methylpyridazine −5.0 kcal/mol −5.0 kcal/mol Cc1c(onc1N)C 4,5-Dimethyl-1,2- oxazol-3-amine −5.1 kcal/mol −5.1 kcal/mol c1ccc(c(c1)O)OCCO 2-(2- Hydroxyethoxy) phenol −5.2 kcal/mol −5.2 kcal/mol c1cc(cnc1)C[NH2+]CCO 2-Hydroxy-N-(3- pyridinylmethyl) ethanaminium −5.3 kcal/mol −5.3 kcal/mol c1ccc(cc1)CCCO 3-Phenyl-1- propanol −5.4 kcal/mol −5.4 kcal/mol C[C@H](CCCC(C)C)O (2R)-6-Methyl-2- heptanol −5.5 kcal/mol −5.5 kcal/mol c1ccc(cc1)OCC(═O)NN 2- Phenoxy- acetohydrazide −5.6 kcal/mol −5.6 kcal/mol CCCCCCCC(═O)NO N- Hydroxyoctanamid −5.7 kcal/mol −5.7 kcal/mol C1CC(C1)C(═O)NN Cyclobutane- carbohydrazide −5.8 kcal/mol −5.8 kcal/mol c1ccc(cc1)NN Phenylhydrazine −5.9 kcal/mol −5.9 kcal/mol C1[C@@H]2C═C[C@H]1NC2═O (1S,4R)-2- Azabicyclo[2.2.1] hept-5-en-3-one −6.0 kcal/mol −6.0 kcal/mol c1ccc(c(c1)C(═O)N)O salicylamide −6.1 kcal/mol −6.1 kcal/mol C1[C@@H]2C[C@@H]3C[C@H]1C[C@H](C2)C3 Adamantane -6.2 kcal/mol -6.2 kcal/mol C1C[C@@H]2C[C@H](C1)C[NH2+]C2 3- Azabicyclo [3.3.1]nonane −6.4 kcal/mol −6.4 kcal/mol Cc1ccccc1/C(═N/O)/N N-Hydroxy-2- methylbenzene- carboximidamide −6.5 kcal/mol −4.9 kcal/mol CC1([C@H]2CC[C@H](C2)C1═C)C (−)-camphene −6.6 kcal/mol −5.4 kcal/mol C1[C@H]2C[C@@H]([C@@H]1C═C2)CO (1S,2S,4S)- Bicyclo[2.2.1]hept- 5-en-2-ylmethanol −6.7 kcal/mol −6.1 kcal/mol C1C═C[C@H]2[C@H]1[C@H]1C[C@@H]2C═C1 Dicyclopentadiene −6.8 kcal/mol −5.0 kcal/mol C1C[C@H]2C[NH2+]C[C@@H]1[C@@H]2O (8-anti)-3- Azabicyclo[3.2.1] octan-8-ol −5.8 kcal/mol −6.9 kcal/mol C1C═C[C@@H]2[C@H]1[C@H]1C[C@@H]2C═C1 (1R,2S,6R,7S)- Tricyclo[5.2.1.02,6] deca-3,8-diene −7.0 kcal/mol −6.0 kcal/mol - In an example, administering to the patient with the one or more conditions can include administering, to the patient with the one or more conditions, a therapeutically effective amount of a compound for inhibiting the CutC enzymes of the microorganisms from Firmicutes (phylum) and Proteobacteria (phylum), where the compound includes at least one (e.g., any one or more; etc.) of: Methyl 4-methyl-4-piperidinecarboxylate; Methyl heptanoate; 3-Methylpyridazine; 4,5-Dimethyl-1,2-oxazol-3-amine; 2-(2-Hydroxyethoxy)phenol; 2-Hydroxy-N-(3-pyridinylmethyl)ethanaminium; 3-Phenyl-1-propanol; (2R)-6-Methyl-2-heptanol; 2-Phenoxyacetohydrazide; N-Hydroxyoctanamid; Cyclobutanecarbohydrazide; Phenylhydrazine; (1S,4R)-2-Azabicyclo[2.2.1]hept-5-en-3-one; salicylamide; Adamantane; 3-Azabicyclo[3.3.1]nonane; N-Hydroxy-2-methylbenzenecarboximidamide; (−)-camphene; (1S,2S,4S)-Bicyclo[2.2.1]hept-5-en-2-ylmethanol; Dicyclopentadiene; (8-anti)-3-Azabicyclo[3.2.1]octan-8-ol; (1R,2S,6R,7S)-Tricyclo[5.2.1.02,6]deca-3,8-diene; and pharmaceutically acceptable forms thereof (e.g., derivatives thereof; pharmaceutically deliverable forms thereof; etc.); and/or salts (e.g., pharmaceutically acceptable salts; etc.) thereof. In an example, compounds including different binding affinities (and/or other suitable interaction parameters) to CutC enzymes depending on the association of the CutC enzyme to a given taxon (e.g., CutC enzymes of microorganisms from Proteobacteria; CutC enzymes of microorganisms from Firmicutes; etc.), and/or compounds with different affinities generally, can enable different applications, such as where a compound with high affinity can exert an irreversible inhibition on the CutC enzyme. However, compounds for inhibiting CutC enzymes of microorganisms from Firmicutes (phylum) and Proteobacteria (phylum) can be configured in any suitable manner, and administering such compounds can be performed in any suitable manner (e.g., for affecting any suitable targets).
- Administering one or more compounds can include administering (e.g., a therapeutically effective amount of; etc.) one or more compounds for inhibiting (and/or otherwise affecting) CntA enzymes, such as CntA enzymes of microorganisms from at least one of Firmicutes (phylum), Proteobacteria (phylum), and/or other suitable taxa. In examples, L-carnitine (e.g., a substrate for CntA enzymes; etc.) can facilitate the production of TMA, TMAO, and/or derivatives thereof through binding to an active site on CntA enzymes, and where L-carnitine can be associated with (e.g., cause, correlated with, influence, etc.) metabolic-related conditions, nutritional-related conditions (e.g., weight-related conditions; high blood sugar-related conditions; etc.), and/or other suitable conditions, such as where compounds inhibiting (and/or otherwise affecting) CntA enzymes can decrease the effect of L-carnitine and/or CntA enzymes in relation to the one or more conditions.
- Compounds for inhibiting (and/or otherwise affecting) CntA enzymes (e.g., associated with microorganisms from at least one of Proteobacteria and Firmicutes; etc.) can include one or more L-carnitine analogues (e.g., binding with equal or higher affinity to CntA enzymes than L-carnitine, such as for CntA enzymes belonging to Proteobacteria and/or Firmicutes; etc.). In examples, the L-carnitine analogues and/or other suitable compounds can bind to CntA enzymes to competitively inhibit the binding of L-carnitine to the CntA enzymes (e.g., where the substrate and inhibitor cannot bind the active site simultaneously; where the competitive inhibition can facilitate decrease in production of TMA, TMAO, and/or derivatives thereof; etc.). In examples, L-carnitine analogues (and/or compounds generally) can include any one or more compounds included in Table 5. Table 5.
-
TABLE 5 Examples of Analogues of L-carnitine that can Bind CntA Enzymes of Microorganisms from Proteobacteria and/or Firmicutes. Binding Energy Binding Energy IUPAC (to CntA enzyme, (to CntA enzyme, Structure SMILES code nomenclature Proteobacteria) Firmicutes) C[NH2+][C@@H](CCC(═O)O)C(═O)O N- Methylglutamic acid −4.9 kcal/mol C1CC[NH+](C1)CCCC(═O)O 4-(1- Pyrrolidinyl) butanoic acid −5.1 kcal/mol CC1(CC[NH2+]CC1)C(═O)O 4-Methyl-4- piperidinecarboxylic acid −4.7 kcal/mol −5.0 kcal/mol C1C[NH2+]CCC1C(═O)O Isonipecotic acid −4.9 kcal/mol - In an example, administering to the patient with the one or more conditions can include administering, to the patient with the one or more conditions, a therapeutically effective amount of a compound including an L-carnitine analogue including at least one (e.g., any one or more; etc.) of: N-Methylglutamic acid; 4-(1-Pyrrolidinyl)butanoic acid; 4-Methyl-4-piperidinecarboxylic acid; Isonipecotic acid; and pharmaceutically acceptable forms thereof (e.g., derivatives thereof; pharmaceutically deliverable forms thereof; etc.); and/or salts (e.g., pharmaceutically acceptable salts; etc.) thereof. However, compounds including an L-carnitine analogue can be configured in any suitable manner, and administering such compounds can be performed in any suitable manner (e.g., for affecting any suitable targets).
- Compounds for inhibiting (and/or otherwise affecting) CntA enzymes can include one or more compounds for inhibiting the CntA enzymes of microorganisms from Firmicutes (phylum), such as where the one or more compounds (and/or compounds generally) can include any one or more compounds included in Table 6 (e.g., where the compounds can include specificity for CntA enzymes from microorganisms from Firmicutes; where the compounds do not bind or bind with lower affinity to CntA enzymes from microorganisms from Proteobacteria; where each compound can be representative of a subset of molecules exerting the same binding energy and such as with similar structure to the compound; where the compounds can include higher affinity, as indicated by the binding energy values, than L-carnitine, to the CntA enzymes; etc.).
-
TABLE 6 Examples of Compounds (e.g., molecules) that can Bind CntA Enzymes of Microorganisms from Firmicutes (e.g., Firmicutes-J3B3E2 CntA Enzyme) Binding Energy IUPAC (to CntA enzyme, Structure SMILES code nomenclature Firmicutes) CCCc1ccccc1 N-propylbenzene −5.8 kcal/mol CCNc1cccc[nH+]1 N-Ethyl-2- pyridinamine −5.7 kcal/mol CCCN1C[C@H](CC1═O)[NH3+] (4R)-4-Amino-1- propyl-2- pyrrolidinone −5.6 kcal/mol Cc1cc(ccc1N)N 2,5- Diaminotoluene −5.5 kcal/mol CCOc1ccccc1 Ethyl phenyl ether −5.4 kcal/mol c1ccc(cc1)OC#N Phenylcyanate −5.3 kcal/mol CC(═O)C[C@@H]1CCC═C1 1-(2-Cyclopenten- 1-yl)acetone −5.2 kcal/mol Cc1ccc[nH+]c1N 2-Amino-3- methylpyridinium −5.1 kcal/mol c1cc(cnc1)/C═N/O E-pyridine-3- aldoxime −5.0 kcal/mol C1CCC(CC1)NC═O N- Cyclohexylformamide −4.9 kcal/mol CCC/C═C(\C)/C(═O)O 2-Methyl-2- hexenoic acid −4.8 kcal/mol CCCC(CCC)[NH3+] 4- Heptanaminium −4.7 kcal/mol - In an example, administering to the patient with the one or more conditions can include administering, to the patient with the one or more conditions, a therapeutically effective amount of a compound for inhibiting the CntA enzymes of the microorganisms from Firmicutes (phylum), where the compound includes at least one (e.g., any one or more; etc.) of: N-propylbenzene; N-Ethyl-2-pyridinamine; (4R)-4-Amino-1-propyl-2-pyrrolidinone; 2,5-Diaminotoluene; Ethyl phenyl ether; Phenylcyanate; 1-(2-Cyclopenten-1-yl)acetone; 2-Amino-3-methylpyridinium; E-pyridine-3-aldoxime; N-Cyclohexylformamide; 2-Methyl-2-hexenoic acid; 4-Heptanaminium; and pharmaceutically acceptable forms thereof (e.g., derivatives thereof; pharmaceutically deliverable forms thereof; etc.); and/or salts (e.g., pharmaceutically acceptable salts; etc.) thereof. However, compounds for inhibiting CntA enzymes of microorganisms from Firmicutes (phylum) can be configured in any suitable manner, and administering such compounds can be performed in any suitable manner (e.g., for affecting any suitable targets).
- Compounds for inhibiting (and/or otherwise affecting) CntA enzymes can include one or more compounds for inhibiting the CntA enzymes of microorganisms from Proteobacteria (phylum), such as where the one or more compounds (and/or compounds generally) can include any one or more compounds included in Table 7 (e.g., where the compounds can include specificity for CntA enzymes from microorganisms from Proteobacteria; where the compounds do not bind or bind with lower affinity to CntA enzymes from microorganisms from Firmicutes; where each compound can be representative of a subset of molecules exerting the same binding energy and such as with similar structure to the compound; where the compounds can include higher affinity, as indicated by the binding energy values, than L-carnitine, to the CntA enzymes; etc.).
-
TABLE 7 Examples of Compounds (e.g., molecules) that can Bind CntA Enzymes of Microorganisms from Proteobacteria (e.g., Proteobacteria-L1LUC3 CntA Enzyme) Binding Energy IUPAC (to CntA enzyme, Structure SMILES code nomenclature Proteobacteria) C(C(═O)O)[C@]1([C@@H](OL)C(═O)O)C(═O) O 3,4-Anhydro-3- carboxy-2-deoxy- L-threo-pentaric acid −4.8 kcal/mol C(CO)[NH+](CC(═O)O)CC(═O)O 2,2′-[(2- Hydroxyethyl)imino] diacetic acid −4.6 kcal/mol C(c1nn[nH]n1)C(═O)O 1H-Tetrazol-5- ylacetic acid −4.5 kcal/mol CC(═O)C(C(═O)C)C(═O)C Diacetylacetone −4.4 kcal/mol C[C@@H](C(═O)O)OC(═O)C (2S)-2- Acetoxypropanoic acid −4.3 kcal/mol - In an example, administering to the patient with the one or more conditions can include administering, to the patient with the one or more conditions, a therapeutically effective amount of a compound for inhibiting the CntA enzymes of the microorganisms from Proteobacteria (phylum), where the compound includes at least one (e.g., any one or more; etc.) of: 3,4-Anhydro-3-carboxy-2-deoxy-L-threo-pentaric acid; 2,2′-[(2-Hydroxyethyl)imino]diacetic acid; 1H-Tetrazol-5-ylacetic acid; Diacetylacetone; (2S)-2-Acetoxypropanoic acid; and pharmaceutically acceptable forms thereof (e.g., derivatives thereof; pharmaceutically deliverable forms thereof; etc.); and/or salts (e.g., pharmaceutically acceptable salts; etc.) thereof. However, compounds for inhibiting CntA enzymes of microorganisms from Proteobacteria (phylum) can be configured in any suitable manner, and administering such compounds can be performed in any suitable manner (e.g., for affecting any suitable targets).
- Compounds for inhibiting (and/or otherwise affecting) CntA enzymes can include one or more compounds for inhibiting the CntA enzymes of microorganisms from Firmicutes (phylum) and Proteobacteria (phylum) (e.g., inhibiting CntA enzymes of first microorganisms from Firmicutes as well as CntA enzymes of second microorganisms from Proteobacteria, etc.), such as where the one or more compounds (and/or compounds generally) can include any one or more compounds included in Table 8 (e.g., compounds binding CntA enzymes associated with Firmicutes, and binding CntA enzymes associated with Proteobacteria; such as where the compounds can inhibit products of TMA by CntA in a set of microorganisms across different taxa, such as across Firmicutes and Proteobacteria; where each compound can be representative of a subset of molecules exerting the same binding energy and such as with similar structure to the compound; where the compounds can include higher affinity, as indicated by the binding energy values, than L-carnitine, to the CntA enzymes; etc.).
-
TABLE 8 Examples of Compounds (e.g., molecules) that can Bind CntA Enzymes of Microorganisms from Proteobacteria and Firmicutes Binding Binding Energy Energy (to CntA (to CntA IUPAC enzyme, enzyme, Structure SMILES code nomenclature Proteobacteria) Firmicutes) c1cc2c(cc1c1ccc3c(c1)C(═O)OC3═O)C(═O)OC2═O 4,4′-Biphthalic anhydride −8.9 kcal/mol −8.9 kcal/mol O═C(n1nnc2ccccc12)n1nnc2ccccc12 Bis(1H- benzotriazol-1- yl)methanone −7.9 kcal/mol −7.9 kcal/mol c1ccc2c(c1)C(═O)c1ccc(cc1C2═O)S(═O)(═O)O 2- Anthra- quinonesulfonic acid −7.8 kcal/mol −7.8 kcal/mol c1ccc2c(c1)C(═O)N(C2═O)c1cccc(c1)C#N 3-(1,3-Dioxo-1,3- dihydro-2H- isoindol-2- yl)benzonitrile. −7.7 kcal/mol −7.7 kcal/mol c1ccc(cc1)c1nc2ccccc2c(═O)[nH]1 2- phenylquinazolin- 4-ol −7.6 kcal/mol −7.6 kcal/mol c1ccc2c(c1)nc(s2)c1cc(ccc1O)N 4-Amino-2-(1,3- benzothiazol-2- yl)phenol −7.5 kcal/mol −7.5 kcal/mol c1ccc(cc1)c1c2ccccc2c(═O)[nH]n1 4-Phenyl-1(2H)- phthalazinone −7.4 kcal/mol −7.4 kcal/mol Cc1c(cc(o1)c1ccc2c(c1)OCO2)C(═O)O 5-(1,3- Benzodioxol-5-yl)- 2-methyl-3-furoic acid −7.3 kcal/mol −7.3 kcal/mol c1ccc2cc(ccc2c1)[C@H]1CCC(═O)O1 (5R)-5-(2- Naphthyl)dihydro- 2(3H)-furanone −7.2 kcal/mol −7.2 kcal/mol Cc1cccc(c1)c1nnc(o1)CCC(═O)O 3-[5-(3- Methylphenyl)- 1,3,4-oxadiazol-2- yl]propanoic acid −7.1 kcal/mol −7.1 kcal/mol C#Cc1cc2ccccc2c2c1cccc2 9- ETHYNYL- PHENANTHRENE −6.9 kcal/mol −6.9 kcal/mol c1cnccc1c1cc2c([nH]1)CCNC2═O PHA-767491 −6.8 kcal/mol −6.8 kcal/mol Cc1c(cccc1O)N 3-Amino-2- methylphenol −6.7 kcal/mol −6.7 kcal/mol Cc1ccc(cc1)c1ccc(o1)C(═O)O 5-(4- Methylphenyl)-2- furoic acid −6.6 kcal/mol −6.6 kcal/mol Cc1ccc2c(c1)c1c(cc(s1)C(═O)O)CO2 8-Methyl-4H- thieno[3,2- c]chromene-2- carboxylic acid −6.5 kcal/mol −6.5 kcal/mol c1ccc(cc1)C(═O)Oc1cccc(c1)O resorcinol monobenzoate −6.4 kcal/mol −6.4 kcal/mol COc1cc(ccc1C═O)c1ccccc1 3-Methoxy-4- biphenyl- carbaldehyde −6.3 kcal/mol −6.3 kcal/mol Cc1c2ccc(cc2oc(═O)c1CC(═O)O)N (7-Amino-4- methyl-2-oxo-2H- chromen-3- yl)acetic acid −6.2 kcal/mol −6.2 kcal/mol c1cc2c(cc1C(═O)C(═O)O)CCC2 2,3-Dihydro-1H- inden-5- yl(oxo)acetic acid −6.1 kcal/mol −6.1 kcal/mol c1ccnc(c1)c1cccc(c1)N 3-(2- Pyridyl)aniline −6.0 kcal/mol −6.0 kcal/mol Cc1nc([nH]n1)c1ccc(cc1)N 4-(3-Methyl-1H- 1,2,4-triazol-5- yl)aniline −5.9 kcal/mol −5.9 kcal/mol c1cc(ccc1c1ccc(cc1)N)N Benzidine −5.8 kcal/mol −5.8 kcal/mol COc1cc(ccc1O)C[C@@H](C(═O)O)[NH3+] (DL)-3-O- Methyldopa −5.7 kcal/mol −5.7 kcal/mol Cc1cc(c(nc1)N)/C═C/C(═O)OC Methyl (2E)-3-(2- amino-5-methyl- 3- pyridinyl)acrylate −5.6 kcal/mol −5.6 kcal/mol Cc1cc2cc(oc2nc1)CO (5-Methylfuro[2,3- b]pyridin-2- yl)methanol −5.5 kcal/mol −5.5 kcal/mol c1ccc2c(c1)OC[C@H](O2)C[NH3+] (2R)-2,3-Dihydro- 1,4-benzodioxin-2- ylmethanaminium −5.4 kcal/mol −5.4 kcal/mol CCC(═O)O[C@H](C)c1ccccc1 R-phenylethyl propionate −5.3 kcal/mol −5.3 kcal/mol CC(C)OC(═O)c1ccccc1 i-propyl benzoate −5.2 kcal/mol −5.2 kcal/mol Cc1ccc(cc1)NC(═O)C 4-Acetotoluide −5.1 kcal/mol −5.1 kcal/mol Cc1ccc(c(c1)[C@H](C)[NH3+])C (1S)-1-(2,5- Dimethylphenyl) ethanaminium −5.0 kcal/mol −5.0 kcal/mol CC1═CCC═C[C@H]1C(═O)O (1R)-2-Methyl- 2,5- cyclohexadiene-1- carboxylic acid −4.9 kcal/mol −4.9 kcal/mol COC(Cc1ccccc1)OC (2,2- Dimethoxy- ethyl)benzene −4.8 kcal/mol −4.8 kcal/mol - In an example, administering to the patient with the one or more conditions can include administering, to the patient with the one or more conditions, a therapeutically effective amount of a compound for inhibiting the CntA enzymes of the microorganisms from Firmicutes (phylum) and Proteobacteria (phylum), where the compound includes at least one (e.g., any one or more; etc.) of: 4,4′-Biphthalic anhydride; Bis(1H-benzotriazol-1-yl)methanone; 2-Anthraquinonesulfonic acid; 3-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)benzonitrile.; 2-phenylquinazolin-4-ol; 4-Amino-2-(1,3-benzothiazol-2-yl)phenol; 4-Phenyl-1(2H)-phthalazinone; 5-(1,3-Benzodioxol-5-yl)-2-methyl-3-furoic acid; (5R)-5-(2-Naphthyl)dihydro-2(3H)-furanone; 3-[5-(3-Methylphenyl)-1,3,4-oxadiazol-2-yl]propanoic acid; 9-ETHYNYLPHENANTHRENE; PHA-767491; 3-Amino-2-methylphenol; 5-(4-Methylphenyl)-2-furoic acid; 8-Methyl-4H-thieno[3,2-c]chromene-2-carboxylic acid; resorcinol monobenzoate; 3-Methoxy-4-biphenylcarbaldehyde; (7-Amino-4-methyl-2-oxo-2H-chromen-3-yl)acetic acid; 2,3-Dihydro-1H-inden-5-yl(oxo)acetic acid; 3-(2-Pyridyl)aniline; 4-(3-Methyl-1H-1,2,4-triazol-5-yl)aniline; Benzidine; (DL)-3-O-Methyldopa; Methyl (2E)-3-(2-amino-5-methyl-3-pyridinyl)acrylate; (5-Methylfuro[2,3-b]pyridin-2-yl)methanol; (2R)-2,3-Dihydro-1,4-benzodioxin-2-ylmethanaminium; R-phenylethyl propionate; i-propyl benzoate; 4-Acetotoluide; (1S)-1-(2,5-Dimethylphenyl)ethanaminium; (1R)-2-Methyl-2,5-cyclohexadiene-1-carboxylic acid; (2,2-Dimethoxyethyl)benzene; and pharmaceutically acceptable forms thereof (e.g., derivatives thereof; pharmaceutically deliverable forms thereof; etc.); and/or salts (e.g., pharmaceutically acceptable salts; etc.) thereof. In an example, compounds including different binding affinities (and/or other suitable interaction parameters) to CntA enzymes depending on the association of the CntA enzyme to a given taxon (e.g., CntA enzymes of microorganisms from Proteobacteria; CntA enzymes of microorganisms from Firmicutes; etc.), and/or compounds with different affinities generally, can enable different applications, such as where a compound with high affinity can exert an irreversible inhibition on the CntA enzyme. However, compounds for inhibiting CntA enzymes of microorganisms from Firmicutes (phylum) and Proteobacteria (phylum) can be configured in any suitable manner, and administering such compounds can be performed in any suitable manner (e.g., for affecting any suitable targets).
- However, compounds can be configured in any suitable manner, and administering one or more compounds Silo can be performed in any suitable manner.
- Additionally or alternatively, embodiments of the
method 100 can include determining one or more representative sequences of one or more targets (e.g., CutC enzymes; CntA enzymes; other enzymes; proteins; other biological targets; non-biological targets; enzymes associated with at least one of TMA, TMAO, and/or derivatives thereof; etc.) S120, which can function to determine representative characteristics of targets for use in modeling and/or experiments for facilitating compound determination. - Representative sequences and/or characteristics can include any one or more of nucleic acid sequence and/or composition; amino acid sequence and/or composition; functional characteristics; structural characteristics (e.g., multi-dimensional structure; etc.); evolutionary characteristics; and/or other suitable characteristics.
- Representative sequences and/or characteristics are preferably determined for one or more targets, but can additionally or alternatively be determined for one or more of control molecules, compounds, and/or any other suitable molecules. In an example representative sequences and/or characteristics can be determined for one or more enzymes, such as where the enzyme can include at least one CutC enzyme and CntA enzyme, and where the representative sequence can be representative of a set of sequences of the enzyme for at least one taxon including at least one of Firmicutes (phylum) and Proteobacteria (phylum).
- Representative sequences and/or characteristics are preferably representative for one or more taxons from a set of microorganism taxa. For example, a representative sequence can be representative of a set of sequences of one or more targets (e.g., CutC enzyme, CntA enzyme, etc.) for one or more microorganism taxa (e.g., Firmicutes and/or Proteobacteria and/or other suitable taxa; etc.). In an example, determining one or more representative sequences can include: generating a sequence similarity network with target sequences (e.g., CutC enzyme sequences; CntA enzyme sequences; etc.) associated with (e.g., belonging to; of microorganisms belonging to; etc.) each taxon of the set of taxa (e.g., associated with both Firmicutes and Proteobacteria), such as in order to identify a representative target sequence for each taxon (e.g., a first representative CutC enzyme sequence for Firmicutes and a second representative CutC enzyme sequence for Proteobacteria; a first representative CntA enzyme sequence for Firmicutes and a second representative CntA enzyme sequence for Proteobacteria; etc.).
- However, determining one or more representative sequences S120 can be performed in any suitable manner.
- Additionally or alternatively, embodiments of the
method 100 can include generating one or more models (e.g., protein structure models; etc.) of the one or more targets based on the one or more representative sequences of the one or more targets S130, which can function to model one or more targets for facilitating experiments useful in compound determinations. - Models preferably include protein structure models (e.g., modeling enzyme targets such as CntA enzymes and/or CutC enzymes; etc.), but can additionally or alternatively include any suitable models (e.g., modeling any suitable types of targets; etc.). Models can include any one or more of computational models, models of any suitable number of dimensions, non-computational models, physical models, virtual reality models, augmented reality models, and/or any suitable types of models. Models can be generating using any suitable processing operations and/or artificial intelligence approaches described herein.
- Generating models is preferably based on representative sequences, such as where characteristics of the representative sequences can be used as inputs and/or parameters for model generation. For example, generating models can include generating protein structure models for both the CutC enzyme from Firmicutes (e.g., Uniprot ID: CoD5P1) (e.g., based on the representative sequence for the CutC enzyme from microorganisms from Firmicutes; etc.) and CutC enzyme from Proteobacteria (e.g., Uniprot ID: B4EYG1) (e.g., based on the representative sequence for the CutC enzyme from microorganisms from Proteobacteria; etc.) using a homology modeling approach (and/or any suitable modeling approach), which can facilitate determination of 3D models (e.g., for proteins lacking crystallographic data; etc.). For example, generating models can include generating protein structure models for both the CntA enzyme from Firmicutes (e.g., Uniprot ID: J3B3E2) (e.g., based on the representative sequence for the CntA enzyme from microorganisms from Firmicutes; etc.) and CntA enzyme from Proteobacteria (e.g., Uniprot ID: L1LUC3) (e.g., based on the representative sequence for the CntA enzyme from microorganisms from Proteobacteria; etc.) using a homology modeling approach (and/or any suitable modeling approach), which can facilitate determination of 3D models (e.g., for proteins lacking crystallographic data; etc.).
- However, generating one or more models S130 can be performed in any suitable manner.
- 2.4 Determining an Interaction Parameter Associated with a Control.
- Additionally or alternatively, embodiments of the
method 100 can include determining one or more control binding parameters (and/or other suitable interaction parameters; etc.) to the one or more targets based on one or more experiments with the one or more models and one or more control molecules S140, which can function to determine characteristics describing interactions between one or more controls and one or more targets. - Types of binding parameters (e.g., control binding parameters; compound binding parameters; etc.) preferably include types of binding parameters included in Tables 1-8 (e.g., binding energy values, affinity energy values, etc.), but can additionally or alternatively include association rate, dissociation rate, half-life of interaction (e.g., between receptor and peptide), binding constants, binding specificity, thermodynamics associated parameters (e.g. enthalpy, entropy, Gibbs free energy), parameters associated with number and type of binding sites (e.g., stoichiometry), parameters associated with undesired binding (e.g., self-assembly, interference with other proteins, etc.), and/or any other suitable binding parameters. include any suitable binding affinity parameters. Interaction parameters preferably include binding affinities, but can additionally or alternatively include any suitable parameters associated with control molecules, compounds, targets, and/or other suitable molecules, and/or associated with interactions between any combination of such molecules.
- Experiments preferably include docking simulations (e.g., docking simulations using the one or more models and simulating the binding of one or more control molecules to the one or more models, such as to the active sites of one or more of the protein structure models for CutC enzymes and/or CntA enzymes; etc.), but can additionally or alternatively include one or more of: other computational simulations (e.g., in silico, etc.); in vitro experiments, in vivo experiments, benchtop experiments, use of computational models, and/or any other suitable other experiments.
- In an example, docking simulations can be performed to determine control binding parameters (e.g., binding energy values for the control molecules; etc.) for choline and DMB in relation to binding CutC enzymes of microorganisms from different taxa (e.g., Firmicutes and/or Proteobacteria; etc.), such as based on performing docking simulations with generated models of the CutC enzymes for the different taxa (e.g., a first model of the CutC enzyme from Firmicutes; a second model of the CutC enzyme from Proteobacteria; etc.) and simulating control molecule (e.g., choline and/or DMB) binding to the generated models. In specific examples, docking simulations can result in binding energy values of −3.7 kcal/mol for choline in relation to CutC enzyme from Firmicutes; −4.8 kcal/mol for DMB in relation to CutC enzyme from Firmicutes; −4.1 kcal/mol for choline in relation to CutC enzyme from Proteobacteria; and −5.2 kcal/mol for DMB in relation to CutC enzyme from Proteobacteria, such as where such binding energy values can indicate a greater affinity of binding for DMB than for choline (e.g., in the context of competitive inhibition; etc.)
- In an example, docking simulations can be performed to determine control binding parameters (e.g., binding energy values for the control molecules; etc.) for L-carnitine in relation to binding CntA enzymes of microorganisms from different taxa (e.g., Firmicutes and/or Proteobacteria; etc.), such as based on performing docking simulations with generated models of the CntA enzymes for the different taxa (e.g., a first model of the CntA enzyme from Firmicutes; a second model of the CntA enzyme from Proteobacteria; etc.) and simulating control molecule (e.g., L-carnitine; DMB; etc.) binding to the generated models. In specific examples, docking simulations can result in binding energy values of −4.5 kcal/mol for L-carnitine in relation to CntA enzyme from Firmicutes; −4.8 kcal/mol for DMB in relation to CntA enzyme from Firmicutes; −4.3 kcal/mol for L-carnitine in relation to CntA enzyme from Proteobacteria; and −5.2 kcal/mol for DMB in relation to CntA enzyme from Proteobacteria.
- Additionally or alternatively, docking simulations can be performed with any suitable models in relation to any suitable control molecules and/or any suitable molecules.
- In examples, determining interaction parameters associated with controls and/or associated with compounds (e.g., in relation to S150), and/or any suitable portions of embodiments of the method 100 (e.g., determining representative sequences S110; generating models S120; etc.) can apply one or more of: extracting features, performing pattern recognition on data, fusing data from multiple sources, combination of values (e.g., averaging values, etc.), compression, conversion (e.g., digital-to-analog conversion, analog-to-digital conversion), performing statistical estimation on data (e.g. ordinary least squares regression, non-negative least squares regression, principal components analysis, ridge regression, etc.), wave modulation, normalization, updating, ranking, weighting, validating, filtering (e.g., for baseline correction, data cropping, etc.), noise reduction, smoothing, filling (e.g., gap filling), aligning, model fitting, binning, windowing, clipping, transformations, mathematical operations (e.g., derivatives, moving averages, summing, subtracting, multiplying, dividing, etc.), data association, multiplexing, demultiplexing, interpolating, extrapolating, clustering, image processing, signal processing, visualizing, and/or any other suitable processing operations.
- In examples, determining interaction parameters associated with controls and/or associated with compounds (e.g., in relation to S150), and/or any suitable portions of embodiments of the method 100 (e.g., determining representative sequences S110; generating models S120; etc.) can apply artificial intelligence approaches (e.g., machine learning approaches, etc.) including any one or more of: supervised learning (e.g., using logistic regression, using back propagation neural networks, using random forests, decision trees, etc.), unsupervised learning (e.g., using an Apriori algorithm, using K-means clustering), semi-supervised learning, a deep learning algorithm (e.g., neural networks, a restricted Boltzmann machine, a deep belief network method, a convolutional neural network method, a recurrent neural network method, stacked auto-encoder method, etc.), reinforcement learning (e.g., using a Q-learning algorithm, using temporal difference learning), a regression algorithm (e.g., ordinary least squares, logistic regression, stepwise regression, multivariate adaptive regression splines, locally estimated scatterplot smoothing, etc.), an instance-based method (e.g., k-nearest neighbor, learning vector quantization, self-organizing map, etc.), a regularization method (e.g., ridge regression, least absolute shrinkage and selection operator, elastic net, etc.), a decision tree learning method (e.g., classification and regression tree, iterative dichotomiser 3, C4.5, chi-squared automatic interaction detection, decision stump, random forest, multivariate adaptive regression splines, gradient boosting machines, etc.), a Bayesian method (e.g., naïve Bayes, averaged one-dependence estimators, Bayesian belief network, etc.), a kernel method (e.g., a support vector machine, a radial basis function, a linear discriminate analysis, etc.), a clustering method (e.g., k-means clustering, expectation maximization, etc.), an associated rule learning algorithm (e.g., an Apriori algorithm, an Eclat algorithm, etc.), an artificial neural network model (e.g., a Perceptron method, a back-propagation method, a Hopfield network method, a self-organizing map method, a learning vector quantization method, etc.), a dimensionality reduction method (e.g., principal component analysis, partial lest squares regression, Sammon mapping, multidimensional scaling, projection pursuit, etc.), an ensemble method (e.g., boosting, bootstrapped aggregation, AdaBoost, stacked generalization, gradient boosting machine method, random forest method, etc.), and/or any suitable artificial intelligence approach.
- Control molecules preferably include one or more of choline, DMB, and/or L-carnitine, but can additionally or alternatively include any suitable substrates that bind to any suitable targets (e.g., substrates binding to CutC enzymes and/or CntA enzymes; etc.), any suitable molecules associated with any suitable targets and/or conditions, and/or any suitable molecules.
- However, determining interaction parameters associated with one or more controls S140 can be performed in any suitable manner.
- 2.5 Determining an Interaction Parameter Associated with a Compound.
- Additionally or alternatively, embodiments of the
method 100 can include determining a set of compound binding parameters (and/or other suitable interaction parameters; etc.) to the one or more targets based on a set of experiments with the one or more models and a library of compounds (e.g., with the potential to affect the one or more targets, such as the potential to inhibit CutC enzymes and/or CntA enzymes; etc.) S150, which can function to determine characteristics describing interactions between one or more compounds (e.g., potential compounds, etc.) and one or more targets. - Compound binding parameters are preferably determined for a library of compounds including any suitable number of compounds. Determining the library of compounds can be based on any suitable parameters (e.g., similarity to structures, number of atoms, and/or other suitable characteristics of control molecules, molecules naturally associated with one or more targets, and/or other suitable molecules; databases of molecules; number of compounds; type of targets; type of conditions; molecules that do not infringe Lipinski rules of druggability; etc.). In an example, determining a library of compounds can include selecting only compounds with a number of atoms similar to (e.g., within a threshold of) a number of atoms of choline, DMB, and/or L-carnitine (e.g., within a limit of 28 atoms; etc.). In a specific example, the library of compounds can include around 24,000 molecules, but can include any suitable number of molecules.
- Determining compound binding parameters and/or other interaction parameters is preferably based on a set of experiments (e.g., types of experiments described in relation to S140), such as based on docking simulations using the one or more generated models (e.g., models for CutC and CntA enzymes for Firmicutes and Proteobacteria) and simulating binding by the compounds in relation to the models.
- Determining compound binding parameters can be used to determine the binding parameters included in Tables 1-8.
- Determining compound binding parameters can be performed in a same, similar, analogous, or different manner than determining control binding parameters.
- However, determining interaction parameters associated with one or more compounds S150 can be performed in any suitable manner.
- Additionally or alternatively, embodiments of the
method 100 can include identifying at least one compound (e.g., from the library of compounds; etc.), based on the one or more control binding parameters and the set of compound binding parameters S160, which can function to identify at least one compound for treating a patient with a condition associated with at least one of trimethylamine (TMA), trimethylamine N-oxide (TMAO), and derivatives thereof, and/or for treating a patient with any suitable conditions. - Identifying compounds is preferably based on a comparison between one or more control binding parameters and the set of compound binding parameters (e.g., filtering a library of compounds for compounds with corresponding compound binding parameters greater than one or more of the control binding parameters, etc.). Additionally or alternatively, identifying compounds can be based on control binding parameters and compound binding parameters in any suitable manner, and/or can be based on an y suitable interaction parameters associated with the one or more control molecules and/or any suitable interaction parameters associated with the compounds.
- In an example, identifying compounds can include selecting, from a library of compounds (e.g., selected based on atom number similarity to choline and/or DMB, within a limit of 28 atoms; etc.), compounds with equal or greater binding affinity (e.g., as indicated by binding energy value; etc.) for CutC enzymes than choline. In an example, compounds (e.g., with equal or greater binding affinity for CutC enzymes than choline; etc.) can be filtered (e.g., further filtered; etc.) based on non-infringement (e.g., non-violation; etc.) of Lipinski rules of druggability, such as including molecular weight <500 Daltons, number of H-bonds donor <5, number of H-bonds acceptor <10, number of N and O atoms <15, range of partition coefficient log P between −2 and 5, number of rotatable bonds <10, number of ring number <10. In an example, compounds (e.g., equal or greater binding affinity for CutC enzymes than choline, and/or not violating Lipinski rules of druggability; etc.) can be filtered (e.g., further filtered; etc.) out if the molecule includes any atoms different from C—H—O—N atoms.
- In an example, identifying compounds can include selecting, from a library of compounds (e.g., selected based on atom number similarity to choline, DMB, and/or L-carnitine, within a limit of 28 atoms; etc.), compounds with equal or greater binding affinity (e.g., as indicated by binding energy value; etc.) for CntA enzymes than L-carnitine. In an example, compounds (e.g., with equal or greater binding affinity for CntA enzymes than L-carnitine; etc.) can be filtered (e.g., further filtered; etc.) based on non-infringement (e.g., non-violation; etc.) of Lipinski rules of druggability, such as including molecular weight <500 Daltons, number of H-bonds donor <5, number of H-bonds acceptor <10, number of N and O atoms <15, range of partition coefficient log P between −2 and 5, number of rotatable bonds <10, number of ring number <10. In an example, compounds (e.g., equal or greater binding affinity for CntA enzymes than L-carnitine, and/or not violating Lipinski rules of druggability; etc.) can be filtered (e.g., further filtered; etc.) out if the molecule includes any atoms different from C—H—O—N atoms.
- In examples, applying such criteria (and/or any suitable criteria) in determining compounds can result in any suitable compounds included in Tables 1-8, such as DMB analogues (e.g., with Tanimoto coefficient >=0.8, and with equal or greater binding affinity than DMB to CutC enzymes from Firmicutes and Proteobacteria; as shown in Table 1; etc.), such as L-carnitine analogues (e.g., with Tanimoto coefficient >=0.7, and with equal or greater binding affinity than L-carnitine to CntA enzymes from Firmicutes and Proteobacteria; as shown in Table 5; etc.).
- Identified compounds are preferably usable for treating patients with one or more conditions associated with the at least one of TMA, TMAO, and derivatives thereof, and/or for treating patients with any suitable conditions. For example, identified compounds can be used in administering a therapeutically effective amount of the one or more compounds (e.g., in relation to Silo). Additionally or alternatively, identified compounds can be used for any suitable purpose.
- However, identifying compounds S160 can be performed in any suitable manner.
- Additionally or alternatively, embodiments of the
method 100 can include validating one or more compounds S170, which can function to experimentally validate and/or otherwise test one or more compounds. - Any suitable compounds described herein can be validated (e.g., experimentally tested, etc.). Compounds can preferably be validated in relation to effect on one or more targets (e.g., CutC enzymes, CntA enzymes, etc.). For example, compounds can be validated in relation to ability of the compounds to inhibit conversion of choline (e.g., in the context of CutC enzymes, etc.) or L-carnitine (e.g., in the context of CntA enzymes) into trimethylamine (TMA) by gut microbiota. As such, compounds can be validated in relation to their ability to treat one or more conditions associated with at least one of trimethylamine (TMA), trimethylamine N-oxide (TMAO), and/or derivatives thereof. However, any suitable molecules described herein can be validated for any suitable purpose, such as by applying any one or more techniques described herein.
- In examples, experiments are carried out using cultures of bacterial strains that produce either CutC/CutD or CntA/CntB enzymes. As an example, cultures of Acinetobacter baumranii (Proteobacteria, aerobic, CntA/CntB producer), Proteus minrabilis, (Proteobacteria, anaerobic, CutC/CutD producer), Sporosarcina newyorkensis DSM 235.40 (Firmicutes, CntA/CntB producer, aerobic) and/or Streptococcus dysgaiactae DSM123147 (Firmicutes, CutC/CutD producer, anaerobic) can be used.
- In an example, an experimental setup includes evaluation of the gradual consumption of either choline and/or L-carnitine, and/or the progressive production of TMA. In a specific example, to quantify the production of (TMA), cultures are set up in triplicate in cell culture flasks, using medium supplemented with carnitine or choline (depending on the case) as a sole carbon source; a sample is taken from each flask at different time points (e.g., t=0, 4, 8, 12, 24 and 48 h; any suitable time points); optical density at 600 nm is obtained for each sample; and TMA, carnitine, and/or choline are quantified for each sample (e.g., corresponding to the different time points; etc.). L-carnitine and choline can quantified in each sample using standard quantification kits (e.g., MAK056 and MAK063, Sigma-Aldrich). TMA quantification can be carried out using cation exchange ion chromatography equipped with a separation column and a conductivity detector.
- Additionally or alternatively, CutC or CntA. TMA lyase activity can be quantified in vitro by incubating, for example: a cell lysate (typically ˜3 mg protein), an isolated enzyme (typically ˜30 μg protein), cultured live microbe (OD600nm˜1.0), and/or over cecal lysate with a d9-labeled synthetic substrate (100 μM, choline or L-carnitine, during 10-16 h). In such cases, TMA lyase activity can be monitored by quantifying d9-TMA production by LC/MS/MS analysis. Additionally or alternatively, TMA production can be detected from supernatants of the culture cells, using cation-exchange ion chromatography. However, any suitable quantification techniques can be applied, such as for validating one or more compounds.
- In a specific example, with obtained baselines of the consumption of L-carnitine and/or choline, and/or the production of TMA, a dose response curve of the control compound DMB (e.g., after incubation by 10-16h) can be obtained on each culture to verify decrease of TMA production; and one or more dose response curves can be obtained for each compound (e.g., described in Tables 1-8; described herein; etc.), such as by incubating the compounds (e.g., 10-16h) into the corresponding intact cell cultures (e.g., where cell lysates and/or isolated enzymes can additionally or alternatively be used), using as substrates L-carnitine and/or choline at different concentrations (e.g., as an example, 20, 40, 60, 80, 100 μM), and then measuring the TMA production at each point. In specific examples, a typical concentration used for the compounds to inhibit production of TMA in an intact cell culture is at the scale of ˜1 mM. In specific examples, compounds reduced TMA production by ˜50% or more at each tested point.
- In a specific example, experiments applying techniques described above can be performed in Escherichia coli lysates expressing either CtutC/CutD or CntA/CntB enzymes from Proteobacteria and/or Firmicutes bacteria species mentioned above.
- In a specific example, TMA lyase (CutC/CntA) inhibitory ability, or IC50, under the presence of claimed compounds can be assessed over isolated enzymes lysates (e.g., at the scale of ˜30 ug), where enzymes can be expressed in a model organism (e.g., E. coli Top10) and later purified. In a specific example, one or more dose response curves can be generated by testing compounds over the isolated enzymes lysates in increasing concentrations in the range between 1 and 1000 μM. In specific examples, IC50 values of compounds are in the range of ˜10 μM.
- Any of the variants described herein (e.g., embodiments, variations, examples, specific examples, figures, etc.) and/or any portion of the variants described herein can be additionally or alternatively combined, aggregated, excluded, used, performed serially, performed in parallel, and/or otherwise applied.
- Portions of embodiments of the
method 100 and/orsystem 200 can be embodied and/or implemented at least in part as a machine configured to receive a computer-readable medium storing computer-readable instructions. The instructions can be executed by computer-executable components that can be integrated with thesystem 200. The computer-readable medium can be stored on any suitable computer-readable media such as RAMs, ROMs, flash memory, EEPROMs, optical devices (CD or DVD), hard drives, floppy drives, or any suitable device. The computer-executable component can be a general or application specific processor, but any suitable dedicated hardware or hardware/firmware combination device can alternatively or additionally execute the instructions. - As a person skilled in the art will recognize from the previous detailed description and from the figures and claims, modifications and changes can be made to embodiments of the
method 100,system 200, and/or variants without departing from the scope defined in the claims.
Claims (23)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/103,830 US20190050525A1 (en) | 2017-08-14 | 2018-08-14 | Rieske-type oxygenase/reductase targeted drugs for diagnostic and treatment of diseases |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762545056P | 2017-08-14 | 2017-08-14 | |
US201762545065P | 2017-08-14 | 2017-08-14 | |
US16/103,830 US20190050525A1 (en) | 2017-08-14 | 2018-08-14 | Rieske-type oxygenase/reductase targeted drugs for diagnostic and treatment of diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190050525A1 true US20190050525A1 (en) | 2019-02-14 |
Family
ID=63449712
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/638,779 Active US11424006B2 (en) | 2017-08-14 | 2018-08-14 | Targeted drugs associated with trimethylamine and/or trimeihylamine-n-oxide |
US16/103,830 Abandoned US20190050525A1 (en) | 2017-08-14 | 2018-08-14 | Rieske-type oxygenase/reductase targeted drugs for diagnostic and treatment of diseases |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/638,779 Active US11424006B2 (en) | 2017-08-14 | 2018-08-14 | Targeted drugs associated with trimethylamine and/or trimeihylamine-n-oxide |
Country Status (8)
Country | Link |
---|---|
US (2) | US11424006B2 (en) |
EP (1) | EP3668494A1 (en) |
JP (1) | JP2020530853A (en) |
KR (1) | KR20200052298A (en) |
CN (1) | CN111163761A (en) |
AU (2) | AU2018317401A1 (en) |
SG (1) | SG11202001332YA (en) |
WO (1) | WO2019036507A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11424006B2 (en) * | 2017-08-14 | 2022-08-23 | Psomagen, Inc. | Targeted drugs associated with trimethylamine and/or trimeihylamine-n-oxide |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3551194B1 (en) * | 2016-12-06 | 2023-10-18 | DSM Nutritional Products, LLC | Glycan polymers and related methods thereof |
KR102629519B1 (en) * | 2023-06-05 | 2024-01-30 | 서무경 | Bacillus amyloliquefaciens strain for improving blood levels of TMAO and TMA elevated by high protein and high choline intake |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5389621A (en) * | 1992-11-18 | 1995-02-14 | University Of Medicine And Dentistry Of New Jersey | Method of enhancing the anticoagulant effects of aspirin using salicylamide |
US20120270899A1 (en) * | 2010-10-29 | 2012-10-25 | Robin Mark Bannister | Compositions and Methods for Treating Cardiovascular Diseases |
WO2013188417A2 (en) * | 2012-06-11 | 2013-12-19 | The Cleveland Clinic Foundation | Treatment and prevention of cardiovascular disease and thrombosis |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003028762A1 (en) * | 2001-09-28 | 2003-04-10 | Ethicon, Inc. | Novel antimicrobial resistance blocking compositions |
US8005620B2 (en) * | 2003-08-01 | 2011-08-23 | Dna Twopointo Inc. | Systems and methods for biopolymer engineering |
ES2774965T3 (en) * | 2013-09-27 | 2020-07-23 | Codexis Inc | Predictive modeling based on structure |
EP3197442B1 (en) * | 2014-09-26 | 2019-07-03 | The Cleveland Clinic Foundation | Treating and preventing disease with tma and tmao lowering agents |
WO2017095975A1 (en) | 2015-12-01 | 2017-06-08 | The Procter & Gamble Company | Compounds and methods for inhibiting production of trimethylamine |
US11424006B2 (en) * | 2017-08-14 | 2022-08-23 | Psomagen, Inc. | Targeted drugs associated with trimethylamine and/or trimeihylamine-n-oxide |
-
2018
- 2018-08-14 US US16/638,779 patent/US11424006B2/en active Active
- 2018-08-14 EP EP18762727.8A patent/EP3668494A1/en active Pending
- 2018-08-14 WO PCT/US2018/046764 patent/WO2019036507A1/en unknown
- 2018-08-14 JP JP2020508997A patent/JP2020530853A/en active Pending
- 2018-08-14 SG SG11202001332YA patent/SG11202001332YA/en unknown
- 2018-08-14 US US16/103,830 patent/US20190050525A1/en not_active Abandoned
- 2018-08-14 AU AU2018317401A patent/AU2018317401A1/en not_active Abandoned
- 2018-08-14 KR KR1020207007438A patent/KR20200052298A/en not_active Application Discontinuation
- 2018-08-14 CN CN201880058884.2A patent/CN111163761A/en active Pending
-
2021
- 2021-11-23 AU AU2021273531A patent/AU2021273531A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5389621A (en) * | 1992-11-18 | 1995-02-14 | University Of Medicine And Dentistry Of New Jersey | Method of enhancing the anticoagulant effects of aspirin using salicylamide |
US20120270899A1 (en) * | 2010-10-29 | 2012-10-25 | Robin Mark Bannister | Compositions and Methods for Treating Cardiovascular Diseases |
WO2013188417A2 (en) * | 2012-06-11 | 2013-12-19 | The Cleveland Clinic Foundation | Treatment and prevention of cardiovascular disease and thrombosis |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11424006B2 (en) * | 2017-08-14 | 2022-08-23 | Psomagen, Inc. | Targeted drugs associated with trimethylamine and/or trimeihylamine-n-oxide |
Also Published As
Publication number | Publication date |
---|---|
JP2020530853A (en) | 2020-10-29 |
AU2018317401A1 (en) | 2020-03-05 |
US11424006B2 (en) | 2022-08-23 |
CN111163761A (en) | 2020-05-15 |
US20210128498A1 (en) | 2021-05-06 |
EP3668494A1 (en) | 2020-06-24 |
WO2019036507A1 (en) | 2019-02-21 |
AU2021273531A1 (en) | 2021-12-16 |
SG11202001332YA (en) | 2020-03-30 |
KR20200052298A (en) | 2020-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Shahmirzadi et al. | Alpha-ketoglutarate, an endogenous metabolite, extends lifespan and compresses morbidity in aging mice | |
US11424006B2 (en) | Targeted drugs associated with trimethylamine and/or trimeihylamine-n-oxide | |
Perdikari et al. | BATLAS: deconvoluting brown adipose tissue | |
Iyer et al. | Dietary and microbial oxazoles induce intestinal inflammation by modulating aryl hydrocarbon receptor responses | |
Pan et al. | Global analysis of protein lysine succinylation profiles and their overlap with lysine acetylation in the marine bacterium Vibrio parahemolyticus | |
Rahn et al. | Inhibition of glutamate carboxypeptidase II (GCPII) activity as a treatment for cognitive impairment in multiple sclerosis | |
Zhang et al. | Asymmetric epigenome maps of subgenomes reveal imbalanced transcription and distinct evolutionary trends in Brassica napus | |
Casey et al. | Analysis of reproducibility of proteome coverage and quantitation using isobaric mass tags (iTRAQ and TMT) | |
Chung et al. | Transient receptor potential channel 6 regulates abnormal cardiac S-nitrosylation in Duchenne muscular dystrophy | |
De Palma et al. | Metabolic modulation induced by chronic hypoxia in rats using a comparative proteomic analysis of skeletal muscle tissue | |
Ahmedi et al. | Limonene inhibits virulence associated traits in Candida albicans: In-vitro and in-silico studies | |
Li et al. | Integrated analysis of transcriptomic and metabolomic data to evaluate responses to hypersalinity stress in the gill of the razor clam (Sinonovacula constricta) | |
Augusto et al. | Double impact: natural molluscicide for schistosomiasis vector control also impedes development of Schistosoma mansoni cercariae into adult parasites | |
Zhao et al. | Integrated analysis about the effects of heat stress on physiological responses and energy metabolism in Gymnocypris chilianensis | |
Bellera et al. | Identification of Levothyroxine Antichagasic Activity through Computer‐Aided Drug Repurposing | |
Zancolli et al. | Convergent evolution of venom gland transcriptomes across Metazoa | |
Zhao et al. | Comprehensive succinylome profiling reveals the pivotal role of lysine succinylation in energy metabolism and quorum sensing of Staphylococcus epidermidis | |
Zhu et al. | First steps toward the giant panda metabolome database: Untargeted metabolomics of feces, urine, serum, and saliva by 1H NMR | |
Fu et al. | The highest-elevation frog provides insights into mechanisms and evolution of defenses against high UV radiation | |
Ansell et al. | Time-dependent transcriptional changes in axenic Giardia duodenalis trophozoites | |
Khari et al. | Candida auris biofilm: a review on model to mechanism conservation | |
Sahu et al. | Cyclooxygenase‐2 as a therapeutic target against human breast cancer: A comprehensive review | |
Armbrecht et al. | Antisense against amyloid-β protein precursor reverses memory deficits and alters gene expression in neurotropic and insulin-signaling pathways in SAMP8 mice | |
Jiang et al. | Nebivolol acts as a S-nitrosoglutathione reductase inhibitor: a new mechanism of action | |
Wang et al. | Lysine succinylation of VBS contributes to sclerotia development and aflatoxin biosynthesis in Aspergillus flavus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: UBIOME, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:APTE, ZACHARY;RICHMAN, JESSICA;ALMONACID, DANIEL;AND OTHERS;SIGNING DATES FROM 20180810 TO 20180814;REEL/FRAME:046649/0113 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: PSOMAGEN, INC., MARYLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:UBIOME, INC.;REEL/FRAME:051586/0274 Effective date: 20191227 |